

Supporting information for

Synthesis and cytostatic activity of 7-arylsulfanyl-7-deazapurine bases and ribonucleosides

Martin Klečka,^{a,b} Lenka Poštová Slavětínská,^b Eva Tloušťová,^b Petr Džubák,^c Marian Hajdúch,^c and Michal Hocek^{*a,b}

^a *Dept. of Organic Chemistry, Faculty of Science, Charles University in Prague, Hlavova 8, CZ-12843 Prague 2, Czech Republic.*

^b *Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences & IOCB Research Center, Flemingovo nam. 2, CZ-16610 Prague 6, Czech Republic, Fax: (+420)220-183-559; Tel: (+420)220-183-324; E-mail: hocek@uochb.cas.cz*

^c *Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Hněvotínská 5, CZ-775 15 Olomouc, Czech Republic*

Contents:

1. Table of cytostatic activities
2. Experimental section
3. Copies of NMR spectra

Table S1. Cytostatic activities of all compounds

	IC ₅₀ (μM)											
	A549	CCRF-CEM	CEM-DNR	HCT116	HCT116p53--	K562	K562-TAX	HepG2	HL60	HeLa S3	BJ	MRC-5
1b	> 50	> 50	> 50	> 50	> 50	> 50	> 50	>25	>25	>25	132.45 ± 27.23	141.14 ± 13.73
1c	48.80 ± 1.85	> 50	> 50	48.29 ± 2.01	48.58 ± 2.19	> 50	> 50	>25	>25	>25	141.72 ± 12.95	138.32 ± 15.75
1d	46.15 ± 3.02	42.40 ± 1.16	> 50	45.05 ± 4.18	44.98 ± 7.40	47.83 ± 3.37	> 50	>25	>25	>25	141.23 ± 8.31	121.28 ± 19.39
1e	> 50	> 50	> 50	> 50	> 50	> 50	> 50	>25	>25	>25	> 150	> 150
1f	> 50	> 50	> 50	> 50	> 50	> 50	> 50	>25	>25	>25	> 150	> 150
1g	49.09 ± 1.39	44.87 ± 1.50	48.14 ± 3.33	40.98 ± 3.79	43.67 ± 5.07	27.23 ± 5.22	49.36 ± 1.56	>25	>25	>25	140.22 ± 11.07	135.79 ± 18.48
1h	> 50	46.91 ± 4.22	> 50	45.03 ± 3.89	47.78 ± 3.69	49.34 ± 1.04	48.28 ± 2.30	>25	>25	>25	> 150	> 150
2b	16.19 ± 1.34	10.55 ± 2.90	17.67 ± 0.53	13.03 ± 3.03	5.06 ± 0.18	5.14 ± 0.18	21.66 ± 1.34	>25	21.1 ± 1.7	>25	23.38 ± 3.57	54.48 ± 9.06
2c	11.43 ± 2.61	7.73 ± 1.36	20.83 ± 1.72	6.75 ± 2.72	19.53 ± 1.23	4.26 ± 0.47	18.90 ± 0.85	>25	7.63 ± 1.1	8.49 ± 2.62	22.06 ± 2.77	32.87 ± 1.79
2d	64.23 ± 2.65	60.85 ± 7.39	56.77 ± 1.44	38.12 ± 32.56	29.10 ± 3.19	13.99 ± 0.59	64.63 ± 2.76	>25	>25	>25	> 150	135.50 ± 17.33
2e	19.80 ± 2.79	14.63 ± 0.55	35.25 ± 2.36	11.01 ± 3.70	27.54 ± 5.08	3.83 ± 0.25	22.14 ± 1.14	>25	>25	>25	144.56 ± 8.46	> 150
2f	28.58 ± 6.38	14.72 ± 0.73	26.15 ± 1.06	18.98 ± 2.77	45.30 ± 2.58	4.95 ± 0.39	21.00 ± 0.44	>25	13.5 ± 0.4	17.6 ± 2.9	132.24 ± 17.89	148.21 ± 2.77
2g	22.82 ± 1.91	16.68 ± 0.98	20.34 ± 1.34	22.79 ± 2.03	86.56 ± 2.40	17.88 ± 0.69	17.92 ± 0.74	>25	13.9 ± 0.6	17.9 ± 1.0	> 150	135.71 ± 22.15
2h	21.47 ± 2.33	18.23 ± 0.99	64.59 ± 2.11	17.15 ± 2.28	65.91 ± 6.13	50.33 ± 6.13	43.95 ± 2.24	>25	>25	23.9 ± 0.6	122.60 ± 26.55	148.13 ± 2.90
7b	62.50 ± 7.32	30.07 ± 2.55	53.04 ± 4.06	53.35 ± 6.10	50.76 ± 3.27	62.54 ± 1.85	65.89 ± 1.40	>25	>25	>25	98.17 ± 7.44	104.633.37
7c	> 50	> 50	> 50	> 50	> 50	> 50	> 50	>25	>25	>25	> 150	> 150
7d	76.41 ± 16.18	98.28 ± 1.89	78.57 ± 11.23	94.98 ± 5.51	> 100	78.79 ± 7.17	> 100	>25	>25	>25	112.55 ± 22.39	113.16 ± 24.20
7e	> 50	> 50	> 50	> 50	> 50	> 50	> 50	>25	>25	>25	> 150	> 150
7f	> 50	> 50	> 50	> 50	> 50	> 50	> 50	>25	>25	>25	> 150	> 150
7g	22.91 ± 3.14	33.96 ± 1.42	> 50	20.80 ± 3.59	22.41 ± 8.45	23.09 ± 6.24	29.62 ± 2.41	>25	>25	>25	67.88 ± 8.49	67.70 ± 14.43
7h	70.02 ± 24.37	68.85 ± 3.31	72.74 ± 2.25	85.0 ± 15.05	99.00 ± 1.55	84.96 ± 1.97	98.06 ± 3.02	>25	>25	>25	116.67 ± 25.82	133.33 ± 25.82
8b	76.96 ± 13.91	48.10 ± 2.91	75.21 ± 5.11	55.23 ± 7.98	47.19 ± 2.64	57.21 ± 3.97	70.45 ± 1.64	>25	>25	>25	109.58 ± 20.62	125.7210.94
8c	74.36 ± 11.67	58.93 ± 2.64	79.59 ± 4.71	81.65 ± 6.33	74.36 ± 3.15	80.81 ± 4.59	72.88 ± 4.64	>25	>25	>25	121.00 ± 6.63	145.70 ± 3.45
8d	83.49 ± 15.90	85.60 ± 5.24	88.42 ± 3.02	97.48 ± 4.37	> 100	96.64 ± 5.21	90.84 ± 4.68	>25	>25	>25	149.86 ± 0.34	> 150
8e	89.58 ± 12.73	96.21 ± 3.61	> 100	> 100	> 100	> 100	88.93 ± 5.14	>25	>25	>25	146.53 ± 8.49	> 150
8f	87.61 ± 14.76	96.69 ± 4.78	> 100	92.56 ± 7.75	> 100	> 100	81.85 ± 2.55	>25	>25	>25	> 150	> 150
8g	43.76 ± 4.93	64.66 ± 1.66	> 100	36.72 ± 7.81	23.18 ± 1.04	23.43 ± 1.13	55.77 ± 2.97	>25	>25	>25	93.59 ± 7.76	138.24 ± 10.63
8h	85.47 ± 6.43	89.29 ± 7.83	83.60 ± 2.00	98.80 ± 2.95	> 100	99.82 ± 0.43	86.69 ± 7.54	>25	>25	>25	141.79 ± 9.86	> 150

1. Experimental Section

General


6-Chloro-7-deazapurine was purchased from commercial supplier and used without any further purification. Dry DMF and THF were used as received from supplier. All compounds were fully characterized by NMR and spectra were recorded on a Bruker Avance II 600 (^1H at 600.1 MHz, ^{13}C at 150.9 MHz) or on a Bruker Avance II 500 (499.8 or 500.0 MHz for ^1H and 125.7 MHz for ^{13}C) spectrometer or on a Bruker Avance II 400 (^1H at 400 MHz, ^{13}C at 100.6 MHz) ^1H and ^{13}C resonances were assigned using H,C-HSQC and H,C-HMBC spectra. The samples were measured in CDCl_3 or DMSO and chemical shifts (in ppm, δ -scale) were referenced to solvent signal ($\delta(^1\text{H}) = 7.26$ ppm, $\delta(^{13}\text{C}) = 77.0$ ppm) or in DMSO ($\delta(^1\text{H}) = 2.50$ ppm, $\delta(^{13}\text{C}) = 39.43$ ppm). Coupling constants (J) are given in Hz. High performance flash chromatography (HPFC) were performed with Biotage SP1 apparatus on KP-Sil columns. Reverse phase - high performance flash chromatography (RP-HPFC) purifications were performed with Biotage SP1 apparatus on KP-C18-HS columns. Optical rotations were measured at 25 °C, $[\alpha]_{\text{D}}$ values are given in $10^{-1}\text{degcm}^2\text{g}^{-1}$. IR spectra (wavenumbers in cm^{-1}) were recorded on Bruker Alpha FT-IR spectrometer using ATR technique. High resolution mass spectra were measured on a LTQ Orbitrap XL (Thermo Fisher Scientific) spectrometer using EI ionization technique. Melting points were determined on a Buchi Melting Point B-545 and are uncorrected. Elemental analyses were measured on PE 2400 Series II CHNS/O (Perkin Elmer, USA, 1999).

Preparation of starting compounds:

Sulfenylation of 7-deazapurines. General Procedure:


A mixture of 6-chloro-7-deazapurine (15.36 g, 100 mmol), disulphides (100 mmol), CuI (1.9 g, 10 mmol) and dtbpy (5.37 g, 20 mmol) in DMF (300 mL) was stirred at 110°C under oxygen for 18 hours until complete consumption of starting material as monitored by TLC. The solution was then cooled to room temperature, diluted with EtOAc (200 mL), washed with 1M solution of sodium salt of EDTA (100 mL). Aqueous solution was then extracted three times with EtOAc and combined organic layers were dried over Na₂SO₄, filtered, and evaporated under vacuum. The crude product was purified by column chromatography on silica gel.

4-Chloro-5-(phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine (6-chloro-7-(phenylsulfanyl)-7-deazapurine) (**1a**)



Diphenyldisulfide (21.83 g, 100 mmol) was used as starting compounds to give product **1a** (22.25 g, 85%) as yellowish solids. Chromatography was started with pure hexane (to remove excess of disulphide) and followed by hexane/EtOAc 5:1 to 1:1. Crystallization from ethanol gave white crystals. ¹H NMR was compared with published data¹.

**4-Chloro-5-[(thiophen-2-yl)sulfanyl]-7H-pyrrolo[2,3-*d*]pyrimidine
(6-chloro-7-[(thiophen-2-yl)sulfanyl]-7-deazapurine) (2a)**




2-Thienyl disulfide (23.04 g, 100 mmol) was used as starting compounds to give product **2a** (25.5 g, 95%) as white solids. Chromatography was started with pure hexane (to remove excess of disulphide) and followed by hexane/EtOAc 5:1 to 1:1

M.p. 176 °C. ¹H NMR (500 MHz, DMSO-*d*₆): 6.98 (dd, 1H, *J*_{4,5} = 5.3 Hz, *J*_{4,3} = 3.6 Hz, H-4-thienyl); 7.21 (dd, 1H, *J*_{3,4} = 3.6 Hz, *J*_{3,5} = 1.3 Hz, H-3-thienyl); 7.51 (dd, 1H, *J*_{5,4} = 5.3 Hz, *J*_{5,3} = 1.3 Hz, H-5-thienyl); 8.06 (s, 1H, H-6); 8.59 (s, 1H, H-2); 13.03 (bs, 1H, NH). ¹³C NMR (125.7 MHz, DMSO-*d*₆): 104.01 (C-5); 115.45 (C-4a); 128.03 (CH-4-thienyl); 129.25 (CH-5-thienyl); 130.61 (CH-3-thienyl); 134.76 (CH-6); 136.71 (C-2-thienyl); 150.92 (C-4); 151.40 (CH-2); 152.76 (C-7a). IR (KBr): 3066, 2944, 2809, 2770, 1601, 1556, 1446, 1401, 1401, 1332, 1239, 1216, 1003, 973, 848, 716, 623. HRMS (ESI) calculated for C₁₀H₇N₃ClS₂: 267.9767; found: 267.9764.

Glycosylation of 7-sulfanyl-7-deazapurines. General Procedure:

7-Sulfanyl-7-deazapurine **1a-2a** (40 mmol) was suspended in acetonitrile (200 ml) and BSA (10.4 ml, 40 mmol) was added. Reaction mixture was stirred for 15 min at rt (during this time clear solution was formed). Then TMSOTf (14.46 ml, 80 mmol) and protected ribofuranose (20.2 g, 40 mmol) were added. Mixture was heated to 80 °C for 6 h. After cooling to rt, the mixture was extracted with EtOAc and water, organic layer was washed with NaHCO₃ and again with water, dried over MgSO₄ and evaporated under reduced pressure. Crude product was purified using column chromatography with chloroform.

**4-Chloro-5-(phenylsulfanyl)-9-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine
(6-chloro-7-(phenylsulfanyl)-9-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)-7-deazapurine)
(3a)**




Reaction of **1a** (10.4 g, 40 mmol) according to the general procedure afforded compound **3a** (13.84 g, 49%) as yellowish foam.

M.p. 89 °C. ^1H NMR (600.1 MHz, CDCl_3): 4.71 (dd, 1H, $J_{\text{gem}} = 12.3$, $J_{5'b,4'} = 3.8$, H-5'b); 4.82 (ddd, 1H, $J_{4',3'} = 4.7$, $J_{4',5'} = 3.8$, 3.1, H-4'); 4.89 (dd, 1H, $J_{\text{gem}} = 12.3$, $J_{5'a,4'} = 3.1$, H-5'a); 6.14 (dd, 1H, $J_{3',2'} = 5.8$, $J_{3',4'} = 4.7$, H-3'); 6.23 (dd, 1H, $J_{2',3'} = 5.8$, $J_{2',1'} = 5.4$, H-2'); 6.66 (d, 1H, $J_{1',2'} = 5.4$, H-1'); 7.12 (m, 2H, H-*o*-Ph); 7.13 (m, 1H, H-*p*-Ph); 7.21 (m, 2H, H-*m*-Ph); 7.37, 7.41, 7.42 ($3 \times \text{m}$, $3 \times 2\text{H}$, H-*m*-Bz); 7.55, 7.59 ($2 \times \text{m}$, 3H, H-*p*-Bz); 7.64 (s, 1H, H-6); 7.93, 8.01, 8.08 ($3 \times \text{m}$, $3 \times 2\text{H}$, H-*o*-Bz); 8.58 (s, 1H, H-2). ^{13}C NMR (150.9 MHz, CDCl_3): 63.47 (CH_2 -5'); 71.43 (CH-3'); 74.09 (CH-2'); 80.64 (CH-4'); 87.17 (CH-1'); 105.38 (C-5); 117.87 (C-4a); 125.92 (CH-*p*-Ph); 127.26 (CH-*o*-Ph); 128.38 (C-*i*-Bz); 128.53, 128.57 (CH-*m*-Bz); 128.67 (C-*i*-Bz); 128.68 (CH-*m*-Bz); 128.99 (CH-*m*-Ph); 129.21 (C-*i*-Bz); 129.66, 129.83, 129.84 (CH-*o*-Bz); 132.79 (CH-6); 133.52, 133.77, 133.81 (CH-*p*-Bz); 137.52 (C-*i*-Ph); 151.81 (CH-2); 152.48 (C-7a); 153.22 (C-4); 165.04, 165.35, 166.12 (CO-Bz). IR (KBr): 3123, 3058, 3028, 3004, 2947, 1727, 1601, 1574, 1541, 1452, 1263, 1123, 1090, 707. HRMS (ESI) calculated for $\text{C}_{38}\text{H}_{28}\text{O}_7\text{N}_3\text{ClNaS}$: 728.1229; found: 728.1233.

4-Chloro-5-(2-thienylsulfanyl)-9-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine
(6-chloro-7-[(thiophen-2-yl)sulfanyl]-9-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)-7-deazapurine) (4a)

To form clear solution double amount of BSA (20.8 ml, 80 mmol) was added.

Reaction of **2a** (10.71 g, 40 mmol) according to the general procedure afforded compound **4a** (8.5 g, 30%) as white foam.




M.p. 72 °C. ^1H NMR (500 MHz, CDCl_3): 4.67 (dd, 1H, $J_{\text{gem}} = 12.2$ Hz, $J_{5'a,4'} = 3.9$ Hz, H-5'a); 4.79 (m, 1H, H-4'); 4.86 (dd, 1H, $J_{\text{gem}} = 12.2$ Hz, $J_{5'b,4'} = 3.1$ Hz, H-5'b); 6.12 (dd, 1H, $J_{3',2'} = 5.8$ Hz, $J_{3',4'} = 4.5$ Hz, H-3'); 6.20 (t, 1H, $J_{2',1'} = J_{2',3'} = 5.7$ Hz, H-2'); 6.61 (d, 1H, $J_{1',2'} = 5.6$ Hz, H-1'); 6.89 (dd, 1H, $J_{4,5} = 5.3$ Hz, $J_{4,3} = 3.6$ Hz, H-4-Sthienyl); 7.15 (dd, 1H, $J_{3,4} = 3.6$ Hz, $J_{3,5} = 1.3$ Hz, H-3-Sthienyl); 7.25 (dd, 1H, $J_{5,4} = 5.3$ Hz, $J_{5,3} = 1.3$ Hz, H-5-Sthienyl); 7.36 and 7.40 (2×m, 2×2H, CH-*m*-Bz); 7.44 (s, 1H, H-6); 7.48 (m, 2H, H-*m*-Bz); 7.51 – 7.64 (m, 3H, H-*p*-Bz); 7.92, 7.99 and 8.10 (3×m, 3×2H, H-*o*-Bz); 8.57 (s, 1H, H-2). ^{13}C NMR (125.7 MHz, CDCl_3): 63.62 (CH_2 -5'); 71.41 (CH -3'); 74.01 (CH -2'); 80.59 (CH -4'); 87.04 (CH -1'); 109.91 (C-5); 117.06 (C-4a); 127.56 (CH -4-Sthienyl); 128.40 (C-*i*-Bz); 128.49 and 128.53 (CH -*m*-Bz); 128.68 (C-*i*-Bz); 128.70 (CH -*m*-Bz); 128.28 (C-*i*-Bz); 129.53 (CH -5-Sthienyl); 129.73, 129.80 and 129.82 (CH -*o*-Bz); 130.00 (CH -6); 132.70 (CH -3-Sthienyl); 133.52, 133.72 and 133.75 (CH -*p*-Bz); 133.86 (C-2-Sthienyl); 151.63 (CH -2); 151.97 (C-7a); 152.90 (C-4); 165.02, 165.32 and 166.09 (CO-Bz). IR (KBr): 3102, 3087, 3066, 3031, 3007, 2950, 1730, 1601, 1583, 1538, 1452, 1314, 1263, 1219, 1120, 1096, 1069, 707. HRMS (ESI) calculated for $\text{C}_{36}\text{H}_{26}\text{O}_7\text{N}_3\text{ClNaS}_2$: 734.0796; found: 734.0793.

General procedure for the Stille coupling

Compound **1a-4a** (1 equiv), tributylstannane (1.2 equiv) and $\text{PdCl}_2(\text{PPh}_3)_2$ (5 mol%) under argon atmosphere were dissolved in anhydrous DMF and heated to 100 °C for 8 h. Then, solvent was evaporated under reduced pressure and crude product was purified using HPFC.


4-(Thiophen-2-yl)-5-(phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine (6-(thiophen-2-yl)-7-(phenylsulfanyl)-7-deazapurine) (**1b**)



Deazapurine **1a** (523 mg, 2 mmol), 2-(tributylstannyl)thiophene (0.762 mL, 2.4 mmol) and 15 mL DMF were used according to the general procedure. Crude product was purified using HPFC (hexane/EtOAc, 0–50% EtOAc) and product **1b** was obtained as yellowish solid (496 mg, 80%). Crystallization in ethanol/ H_2O gave yellowish needles.

M.p. 240 °C. ^1H NMR (600.1 MHz, $\text{DMSO}-d_6$): 6.92 (m, 2H, H-*o*-Ph); 7.03 (m, 1H, H-*p*-Ph); 7.07 (dd, 1H, $J_{4,5} = 5.1$, $J_{4,3} = 3.8$, H-4-thienyl); 7.15 (m, 2H, H-*m*-Ph); 7.69 (dd, 1H, $J_{5,4} = 5.1$, $J_{5,3} = 1.1$, H-5-thienyl); 8.10 (s, 1H, H-6); 8.39 (dd, 1H, $J_{3,4} = 3.8$, $J_{3,5} = 1.1$, H-3-thienyl); 8.78 (s, 1H, H-2); 12.93 (bs, 1H, NH). ^{13}C NMR (150.9 MHz, $\text{DMSO}-d_6$): 98.90 (C-5); 113.95 (C-4a); 128.11 (CH-*p*-Ph); 125.64 (CH-*o*-Ph); 128.11 (CH-4-thienyl); 129.18 (CH-*m*-Ph); 130.66 (CH-5-thienyl); 131.87 (CH-3-thienyl); 136.84 (CH-6); 139.19 (C-*i*-Ph); 141.57 (C-2-thienyl); 151.15 (CH-2); 152.10 (C-4); 154.33 (C-7a). IR (KBr): 3105, 2986, 2869, 2827, 1595, 1541, 1479, 1431, 1308, 1260, 806, 740, 707. HRMS (ESI) calculated for $\text{C}_{16}\text{H}_{12}\text{N}_3\text{S}_2$: 310.0468; found: 310.0467. Anal. calculated for $\text{C}_{16}\text{H}_{11}\text{N}_3\text{S}_2 \cdot 0.15\text{H}_2\text{O}$: C, 61.57; H, 3.65; N, 13.46; S, 20.54. Found: C, 61.85; H, 3.55; N, 13.39; S, 20.26.


**4-(Furan-2-yl)-5-(phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine
(6-(furan-2-yl)-7-(phenylsulfanyl)-7-deazapurine) (1c)**



Deazapurine **1a** (523 mg, 2 mmol), 2-(tributylstannyl)furan (0.755 mL, 2.4 mmol) and 15 mL DMF were used according to the general procedure. Crude product was purified using HPFC (hexane/EtOAc, 0–50% EtOAc) and product **1c** was obtained as yellowish solid (510 mg, 87%). Crystallization in ethanol/H₂O gave yellowish needles.

M.p. 234 °C. ¹H NMR (500.0 MHz, DMSO-*d*₆): 7.58 (dd, 1H, *J*_{4,3} = 3.4, *J*_{4,5} = 1.7, H-4-furyl); 6.99 (m, 2H, H-*o*-Ph); 7.03 (m, 1H, H-*p*-Ph); 7.16 (m, 2H, H-*m*-Ph); 7.40 (dd, 1H, *J*_{3,4} = 3.4, *J*_{3,5} = 0.8, H-3-furyl); 7.70 (dd, 1H, *J*_{5,4} = 1.7, *J*_{5,3} = 0.8, H-5-furyl); 8.05 (s, 1H, H-6); 8.81 (s, 1H, H-2); 12.87 (bs, 1H, NH). ¹³C NMR (150.9 MHz, DMSO-*d*₆): 99.51 (C-5); 112.27 (CH-4-furyl); 113.48 (C-4a); 114.77 (CH-3-furyl); 125.14 (CH-*p*-Ph); 125.65 (CH-*o*-Ph); 129.01 (CH-*m*-Ph); 136.57 (CH-6); 139.69 (C-*i*-Ph); 145.53 (CH-5-furyl); 147.73 (C-4); 150.92 (C-2-furyl); 151.32 (CH-2); 154.33 (C-7a). IR (KBr): 3108, 2989, 2869, 2821, 1580, 1541, 1479, 1443, 1314, 827, 731. HRMS (ESI) calculated for C₁₆H₁₂ON₃S: 294.0696; found: 294.0696. Anal. calculated for C₁₆H₁₁N₃OS·0.25H₂O: C, 64.52; H, 3.89; N, 14.11; S, 10.76. Found: C, 64.65; H, 3.73; N, 13.99; S, 10.47.


**4-(Thiophen-2-yl)-5-[(thiophen-2-yl)sulfanyl]-7H-pyrrolo[2,3-d]pyrimidine
(6-(thiophen-2-yl)-7-[(thiophen-2-yl)sulfanyl]-7-deazapurine) (2b)**



Deazapurine **2a** (535 mg, 2 mmol), 2-(tributylstannyl)thiophene (0.762 mL, 2.4 mmol) and 15 mL DMF were used according to the general procedure. Crude product was purified using HPFC (EtOAc/MeOH, 0–5% MeOH) and product **2b** was obtained as yellowish solid (360 mg, 57%).

M.p. 224 °C. ^1H NMR (500 MHz, DMSO- d_6): 6.78 (dd, 1H, $J_{3,4} = 3.6$ Hz, $J_{3,5} = 1.3$ Hz, H-3-Sthienyl); 6.84 (dd, 1H, $J_{4,5} = 5.3$ Hz, $J_{4,3} = 3.6$ Hz, H-4-Sthienyl); 7.29 (dd, 1H, $J_{4,5} = 5.1$ Hz, $J_{4,3} = 3.7$ Hz, H-4-thienyl); 7.39 (dd, 1H, $J_{5,4} = 5.3$ Hz, $J_{5,3} = 1.3$ Hz, H-5-Sthienyl); 7.84 (dd, 1H, $J_{5,4} = 5.1$ Hz, $J_{5,3} = 1.1$ Hz, H-5-thienyl); 8.07 (s, 1H, H-6); 8.44 (dd, 1H, $J_{3,4} = 3.7$ Hz, $J_{3,5} = 1.1$ Hz, H-3-thienyl); 8.76 (s, 1H, H-2); 12.83 (bs, 1H, NH). ^{13}C NMR (150.9 MHz, DMSO- d_6): 103.50 (C-5); 113.19 (C-4a); 127.76 (CH-4-Sthienyl); 128.21 (CH-4-thienyl); 129.08 (CH-5-Sthienyl); 129.85 (CH-3-Sthienyl); 160.73 (CH-5-thienyl); 132.46 (CH-3-thienyl); 135.19 (CH-6); 137.15 (C-2-Sthienyl); 141.41 (C-2-thienyl); 151.16 (CH-2); 152.01 (C-4); 153.80 (C-7a). IR (KBr): 2977, 2860, 2812, 1598, 1547, 1443, 1320, 809, 701. HRMS (ESI) calculated for $\text{C}_{14}\text{H}_{10}\text{N}_3\text{S}_3$: 316.0031; found: 316.0033.

**4-(Furan-2-yl)-5-[(thiophen-2-yl)sulfanyl]-7H-pyrrolo[2,3-*d*]pyrimidine
(6-(furan-2-yl)-7-[(thiophen-2-yl)sulfanyl]-7-deazapurine) (**2c**)**




Deazapurine **2a** (535 mg, 2 mmol), 2-(tributylstannyl)furan (0.755 mL, 2.4 mmol) and 15 mL DMF were used according to the general procedure. Crude product was purified using HPFC (EtOAc/MeOH, 0–5% MeOH) and product **2c** was obtained as yellowish solid (434 mg, 72%).

M.p. 201 °C. ^1H NMR (500 MHz, DMSO- d_6): 6.76 (dd, 1H, $J_{4,3} = 3.5$ Hz, $J_{4,5} = 1.7$ Hz, H-4-furyl); 6.92 (dd, 1H, $J_{4,5} = 5.3$ Hz, $J_{4,3} = 3.6$ Hz, H-4-Sthienyl); 6.99 (dd, 1H, $J_{3,4} = 3.6$ Hz, $J_{3,5} = 1.3$ Hz, H-3-Sthienyl); 7.45 (dd, 1H, $J_{5,4} = 5.3$ Hz, $J_{5,3} = 1.3$ Hz, H-5-Sthienyl); 7.48 (dd, 1H, $J_{3,4} = 3.5$ Hz, $J_{3,5} = 0.8$ Hz, H-3-furyl); 7.84 (s, 1H, H-6); 8.02 (dd, 1H, $J_{5,4} = 1.7$ Hz, $J_{5,3} = 0.8$ Hz, H-5-furyl); 8.77 (s, 1H, H-2); 12.70 (vbs, 1H, NH). ^{13}C NMR (125.7 MHz, DMSO-

d₆): 104.76 (C-5); 112.39 (C-4a); 112.56 (CH-4-furyl); 114.86 (CH-3-furyl); 127.86 (CH-4-Sthienyl); 129.24 (CH-5-Sthienyl); 130.57 (CH-3-Sthienyl); 133.65 (CH-6); 136.87 (C-2-Sthienyl); 145.80 (CH-5-furyl); 147.52 (C-4); 151.18 (C-2-furyl); 151.26 (CH-2); 153.75 (C-7a). IR (KBr): 3105, 2989, 2860, 2830, 1601, 1586, 1532, 1317, 824, 749. HRMS (ESI) calculated for C₁₄H₁₀ON₃S₂: 300.0260; found: 300.0261.

4-(Thiophen-2-yl)-5-(phenylsulfanyl)-7-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine

(6-(thiophen-2-yl)-7-(phenylsulfanyl)-9-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-7-deazapurine) (3b)




Nucleoside **3a** (706 mg, 1 mmol), 2-(tributylstannyl)thiophene (0.381 mL, 1.2 mmol) and 10 mL DMF were used according to the general procedure. Crude product was purified using HPFC (hexane/EtOAc, 0–20% EtOAc) and product **3b** was obtained as yellowish solid (540 mg, 72%).

M.p. 76 °C. ¹H NMR (500.0 MHz, CDCl₃): 4.73 (dd, 1H, *J*_{gem} = 12.2, *J*_{5'b,4'} = 3.7, H-5'b); 4.83 (ddd, 1H, *J*_{4',3'} = 4.6, *J*_{4',5'} = 3.7, 3.1, H-4'); 4.90 (dd, 1H, *J*_{gem} = 12.2, *J*_{5'a,4'} = 3.1, H-5'a); 6.16 (dd, 1H, *J*_{3',2'} = 5.8, *J*_{3',4'} = 4.6, H-3'); 6.26 (dd, 1H, *J*_{2',3'} = 5.8, *J*_{2',1'} = 5.6, H-2'); 6.80 (d, 1H, *J*_{1',2'} = 5.6, H-1'); 6.90 (m, 2H, H-*o*-Ph); 7.01 (dd, 1H, *J*_{4,5} = 5.1, *J*_{4,3} = 3.8, H-4-thienyl); 7.02 (m, 1H, H-*p*-Ph); 7.07 (m, 2H, H-*m*-Ph); 7.36, 7.39, 7.41 (3 × m, 3 × 2H, H-*m*-Bz); 7.42 (dd, 1H, *J*_{5,4} = 5.1, *J*_{5,3} = 1.1, H-5-thienyl); 7.54, 7.55, 7.59 (3 × m, 3 × 1H, H-*p*-Bz); 7.71 (s, 1H,

H-6); 7.95, 8.02, 8.10 ($3 \times m$, $3 \times 2H$, H-*o*-Bz); 8.20 (dd, 1H, $J_{3,4} = 3.8$, $J_{3,5} = 1.1$, H-3-thienyl); 8.84 (s, 1H, H-2). ^{13}C NMR (125.7 MHz, $CDCl_3$): 63.63 (CH_2 -5'); 71.50 (CH -3'); 74.04 (CH -2'); 80.48 (CH -4'); 86.54 (CH -1'); 104.35 (C-5); 115.63 (C-4a); 125.55 (CH -*p*-Ph); 126.70 (CH -*o*-Ph); 127.68 (CH -4-thienyl); 128.49, 128.53, 128.65 (C-*i*-Bz, CH -*m*-Bz); 128.78 (CH -*m*-Ph); 129.23 (C-*i*-Bz); 129.66, 129.83, 129.85 (CH -*o*-Bz); 129.93 (CH -5-thienyl); 132.57 (CH -3-thienyl); 133.24 (CH -6); 133.44, 133.72 (CH -*p*-Bz); 137.57 (C-*i*-Ph); 140.15 (C-2-thienyl); 151.64 (CH -2); 153.48 (C-7a); 154.15 (C-4); 165.07, 165.37, 166.15 (CO-Bz). IR (KBr): 3055, 3040, 3004, 2950, 2923, 1730, 1541, 1452, 1440, 1317, 1263, 1126, 1093, 1069, 1024, 704. HRMS (ESI) calculated for $C_{42}H_{32}O_7N_3S_2$: 754.1676; found: 754.1682.

4-(Furan-2-yl)-5-(phenylsulfanyl)-7-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine

(6-(furan-2-yl)-7-(phenylsulfanyl)-9-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)-7-deazapurine) (3c)




Nucleoside **3a** (706 mg, 1 mmol), 2-(tributylstannyl)furan (0.378 mL, 1.2 mmol) and 10 mL DMF were used according to the general procedure. Crude product was purified using HPFC (hexane/EtOAc, 0–20% EtOAc) and product **3c** was obtained as yellowish solid (677 mg, 92%).

M.p. 67 °C. 1H NMR (500.0 MHz, $CDCl_3$): 4.72 (dd, 1H, $J_{gem} = 12.2$ Hz, $J_{5'a,4'} = 3.8$ Hz, H-5'a); 4.82 (bdt, 1H, $J_{4',3'} = 4.6$ Hz, $J_{4',5'a} = J_{4',5'b} = 3.4$ Hz, H-4'); 4.88 (dd, 1H, $J_{gem} = 12.2$ Hz,

$J_{5'b,4'} = 3.1$ Hz, H-5'b); 6.15 (bdd, 1H, $J_{3',2'} = 5.9$ Hz, $J_{3',4'} = 4.6$ Hz, H-3'); 6.25 (t, 1H, $J_{2',1'} = J_{2',3'} = 5.7$ Hz, H-2'); 6.45 (dd, 1H, $J_{4,3} = 3.5$ Hz, $J_{4,5} = 1.7$ Hz, H-4-furyl); 6.77 (d, 1H, $J_{1',2'} = 5.5$ Hz, H-1'); 7.01 (m, 2H, H-*o*-SPh); 7.04 (m, 1H, H-*p*-SPh); 7.12 (m, 2H, H-*m*-SPh); 7.34 – 7.44 (m, 6H, CH-*m*-Bz); 7.45 (dd, 1H, $J_{5,4} = 1.7$ Hz, $J_{5,3} = 0.8$ Hz, H-5-furyl); 7.57 (dd, 1H, $J_{3,4} = 3.5$ Hz, $J_{3,5} = 0.8$ Hz, H-3-furyl); 7.50 – 7.61 (m, 3H, H-*p*-Bz); 7.67 (s, 1H, H-6); 7.94, 8.01 and 8.09 (3×m, 3×2H, H-*o*-Bz); 8.87 (s, 1H, H-2). ^{13}C NMR (125.7 MHz, CDCl_3): 63.62 ($\text{CH}_2\text{-5'}$); 71.48 (CH-3'); 74.05 (CH-2'); 80.44 (CH-4'); 86.60 (CH-1'); 104.34 (C-5); 112.04 (CH-4-furyl); 144.95 (C-4a); 116.15 (CH-3-furyl); 125.43 ($\text{CH-}p\text{-SPh}$); 126.46 ($\text{CH-}o\text{-SPh}$); 128.48 (C-*i*-Bz); 128.49, 128.54 and 128.64 ($\text{CH-}m\text{-Bz}$); 128.72 (C-*i*-Bz); 128.81 ($\text{CH-}m\text{-SPh}$); 129.23 (C-*i*-Bz); 129.66, 129.83 and 129.85 ($\text{CH-}o\text{-Bz}$); 133.39 (CH-6); 133.42, 133.71 and 133.72 ($\text{CH-}p\text{-Bz}$); 138.27 (C-*i*-SPh); 145.11 (CH-5-furyl); 149.26 (C-4); 150.26 (C-2-furyl); 151.84 (CH-2); 153.59 (C-7a); 165.06, 165.37 and 166.16 (CO-Bz). IR (KBr): 3117, 3063, 3031, 2959, 2920, 2857, 1730, 1538, 1452, 1317, 1263, 1120, 1093, 707. HRMS (ESI) calculated for $\text{C}_{42}\text{H}_{32}\text{O}_8\text{N}_3\text{S}$: 738.1905; found: 738.1908.

4-(Thiophen-2-yl)-5-[(thiophen-2-yl)sulfanyl]-7-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine


(6-(thiophen-2-yl)-7-[(thiophen-2-yl)sulfanyl]-9-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)-7-deazapurine) (4b)



Nucleoside **4a** (712 mg, 1 mmol), 2-(tributylstannyl)thiophene (0.381 mL, 1.2 mmol) and 10 mL DMF were used according to the general procedure. Crude product was purified using HPFC with pure DCM and product **4b** was obtained as yellowish solid (595 mg, 78%).

M.p. 77 °C. ¹H NMR (500 MHz, CDCl₃): 4.70 (dd, 1H, $J_{gem} = 12.2$ Hz, $J_{5'a,4'} = 3.9$ Hz, H-5'a); 4.81 (m, 1H, H-4'); 4.87 (dd, 1H, $J_{gem} = 12.2$ Hz, $J_{5'b,4'} = 3.1$ Hz, H-5'b); 6.12 (dd, 1H, $J_{3',2'} = 5.8$ Hz, $J_{3',4'} = 4.3$ Hz, H-3'); 6.18 (t, 1H, $J_{2',1'} = J_{2',3'} = 5.8$ Hz, H-2'); 6.67 (dd, 1H, $J_{3,4} = 3.6$ Hz, $J_{3,5} = 1.3$ Hz, H-3-Sthienyl); 6.73 (dd, 1H, $J_{4,5} = 5.3$ Hz, $J_{4,3} = 3.6$ Hz, H-4-Sthienyl); 6.76 (d, 1H, $J_{1',2'} = 5.8$ Hz, H-1'); 7.13 (dd, 1H, $J_{5,4} = 5.3$ Hz, $J_{5,3} = 1.3$ Hz, H-5-Sthienyl); 7.24 (dd, 1H, $J_{4,5} = 5.1$ Hz, $J_{4,3} = 3.7$ Hz, H-4-thienyl); 7.37, 7.41 and 7.49 (3×m, 3×2H, H-*m*-Bz); 7.52 – 7.65 (m, 4H, H-*p*-Bz, H-5-thienyl); 7.58 (s, 1H, H-6); 7.93, 8.00 and 8.14 (3×m, 3×2H, H-*o*-Bz); 8.26 (dd, 1H, $J_{3,4} = 3.8$ Hz, $J_{3,5} = 1.2$ Hz, H-3-thienyl); 8.86 (s, 1H, H-2). ¹³C NMR (125.7 MHz, CDCl₃): 63.78 (CH₂-5'); 71.53 (CH-3'); 74.07 (CH-2'); 80.63 (CH-4'); 86.42 (CH-1'); 109.61 (C-5); 114.89 (C-4a); 127.33 (CH-4-Sthienyl); 127.94 (CH-4-thienyl); 128.42 (C-*i*-Bz); 128.51 and 128.55 (CH-*m*-Bz); 128.71 (C-*i*-Bz); 128.76 (CH-*m*-Bz); 129.32 (C-*i*-Bz); 129.42 (CH-5-Sthienyl); 129.77, 129.84 and 129.87 (CH-*o*-Bz); 130.77 (CH-5-thienyl); 131.07 (CH-6); 132.19 (CH-3-Sthienyl); 133.45 (CH-3-thienyl); 133.54, 133.74 and 133.76 (CH-*p*-Bz); 133.5 (C-2-thienyl); 134.09 (C-2-Sthienyl); 150.91 (CH-2); 153.03 (C-4,7a); 165.08, 165.38 and 166.14 (CO-Bz). IR (KBr): 3108, 3060, 3037, 3007, 2953, 2926, 2851, 1727, 1550, 1455, 1317, 1269, 1126, 1090, 1066, 1030, 713. HRMS (ESI) calculated for C₄₀H₃₀O₇N₃S₃: 760.1240; found: 760.1243.

4-(Furan-2-yl)-5-[(thiophen-2-yl)sulfanyl]-7-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine
(6-(furan-2-yl)-7-[(thiophen-2-yl)sulfanyl]-9-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-7-deazapurine) (4c)




Nucleoside **4a** (712 mg, 1 mmol), 2-(tributylstannyl)furan (0.378 mL mg, 1.2 mmol) and 10 mL DMF were used according to the general procedure. Crude product was purified using HPFC with pure DCM and product **4c** obtained as yellowish solid (303 mg, 41%).

M.p. 64 °C. ^1H NMR (500 MHz, CDCl_3): 4.67 (dd, 1H, $J_{\text{gem}} = 12.0$ Hz, $J_{5'a,4'} = 3.9$ Hz, H-5'a); 4.78 (m, 1H, H-4'); 4.81 (dd, 1H, $J_{\text{gem}} = 12.0$ Hz, $J_{5'b,4'} = 3.2$ Hz, H-5'b); 6.12 (dd, 1H, $J_{3',2'} = 5.8$ Hz, $J_{3',4'} = 4.4$ Hz, H-3'); 6.19 (t, 1H, $J_{2',1'} = J_{2',3'} = 5.7$ Hz, H-2'); 6.64 (dd, 1H, $J_{4,3} = 3.5$ Hz, $J_{4,5} = 1.8$ Hz, H-4-furyl); 6.70 (d, 1H, $J_{1',2'} = 5.7$ Hz, H-1'); 6.81 (dd, 1H, $J_{4,5} = 5.3$ Hz, $J_{4,3} = 3.6$ Hz, H-4-Sthienyl); 6.93 (dd, 1H, $J_{3,4} = 3.6$ Hz, $J_{3,5} = 1.3$ Hz, H-3-Sthienyl); 7.18 (dd, 1H, $J_{5,4} = 5.3$ Hz, $J_{5,3} = 1.3$ Hz, H-5-Sthienyl); 7.34 (s, 1H, H-6); 7.36, 7.40 and 7.48 (3×m, 3×2H, H-*m*-Bz); 7.51 - 7.62 (m, 3H, H-*p*-Bz); 7.60 (dd, 1H, $J_{3,4} = 3.5$ Hz, $J_{3,5} = 0.9$ Hz, H-3-furyl); 7.74 (dd, 1H, $J_{5,4} = 1.8$ Hz, $J_{5,3} = 0.9$ Hz, H-5-furyl); 7.93, 7.99 and 8.12 (3×m, 3×2H, H-*o*-Bz); 8.83 (s, 1H, H-2). ^{13}C NMR (125.7 MHz, CDCl_3): 63.88 ($\text{CH}_2\text{-5'}$); 71.53 (CH-3'); 73.99 (CH-2'); 80.39 (CH-4'); 86.44 (CH-1'); 110.33 (C-5); 112.30 (CH-4-furyl); 113.79 (C-4a); 115.70 (CH-3-furyl); 127.47 (CH-4-Sthienyl); 128.45 and 128.51 ($\text{CH-}m\text{-Bz}$); 128.57 (C-*i*-Bz); 128.67 ($\text{CH-}m\text{-Bz}$); 128.80 (C-*i*-Bz); 129.16 (CH-6); 129.40 (C-*i*-Bz); 129.49 (CH-5-Sthienyl); 129.79, 129.82 and 129.86 ($\text{CH-}o\text{-Bz}$); 131.61 (CH-3-Sthienyl); 133.42 and 133.65 ($\text{CH-}p\text{-Bz}$); 134.30 (C-2-Sthienyl); 145.11 (CH-5-furyl); 148.86 (C-4); 150.90 (C-2-furyl); 151.70 (CH-2); 153.18 (C-7a); 165.05, 165.35 and 166.13 (CO-Bz). IR (KBr): 3102, 3055, 3034, 3004, 2956, 2926, 2866, 2851, 1733, 1562, 1535, 1452, 1269, 1123, 1099, 713. HRMS (ESI) calculated for $\text{C}_{40}\text{H}_{30}\text{O}_8\text{N}_3\text{S}_2$: 744.1469; found: 744.1471.

General procedure for methylation

Me₃Al (3 equiv, 2 M in toluene) was added to solution of compound **1a-4a** (1 equiv), and Pd(PPh₃)₄ (5 mol%) in THF. The reaction mixture was stirred at 70 °C for 12 h. Then the solution was dropped in water (decomposition of Me₃Al) and extracted three times with EtOAc and combined organic layers were dried over Na₂SO₄, filtered, and evaporated under vacuum. The crude product was purified by HPFC.


4-Methyl-5-(phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine (6-methyl-7-(phenylsulfanyl)-7-deazapurine) (**1d**)



Deazapurine **1a** (523 mg, 2 mmol), Me₃Al (3 mL, 6 mmol, 2 M in toluene) and 40 mL THF were used according to the general procedure. Crude product was purified using HPFC (hexane/EtOAc, 0–50% EtOAc) and product **1d** was obtained as yellowish solid (355 mg, 73%). Crystallization in ethanol/H₂O gave yellowish needles.

M.p. 230 °C. ¹H NMR (500.0 MHz, DMSO-*d*₆): 2.60 (s, 3H, CH₃); 7.03 (m, 2H, H-*o*-Ph); 7.12 (m, 1H, H-*p*-Ph); 7.25 (m, 2H, H-*m*-Ph); 7.95 (s, 1H, H-6); 8.66 (s, 1H, H-2); 12.64 (bs, 1H, NH). ¹³C NMR (125.7 MHz, DMSO-*d*₆): 20.89 (CH₃); 98.18 (C-5); 117.17 (C-4a); 125.46 (CH-*o*-Ph); 125.49 (CH-*p*-Ph); 129.44 (CH-*m*-Ph); 134.49 (CH-6); 139.52 (C-*i*-Ph); 151.82 (CH-2); 152.26 (C-7a); 159.36 (C-4). IR (KBr): 3123, 2986, 2842, 1577, 1473, 1434, 1332, 1263, 1227, 737. HRMS (ESI) calculated for C₁₃H₁₂N₃S: 242.0746; found: 242.0747. Anal. calculated for C₁₃H₁₁N₃S·0.25H₂O: C, 63.52; H, 4.72; N, 17.09; S, 13.04. Found: C, 63.48; H, 4.49; N, 16.93; S, 13.28.


**4-Methyl-5-[(thiophen-2-yl)sulfanyl]-7H-pyrrolo[2,3-*d*]pyrimidine
(6-methyl-7-[(thiophen-2-yl)sulfanyl]-7-deazapurine) (2d)**



Deazapurine **2a** (535 mg, 2 mmol), Me₃Al (3 mL, 6 mmol, 2 M in toluene) and 40 mL THF were used according to the general procedure. Crude product was purified using HPFC (EtOAc/MeOH, 0–5% MeOH) and product **2d** was obtained as yellowish solid (325 mg, 66%).

M.p. 198 °C. ¹H NMR (500 MHz, DMSO-*d*₆): 2.81 (s, 3H, CH₃-4); 6.98 (dd, 1H, *J*_{4,5} = 5.3 Hz, *J*_{4,3} = 3.6 Hz, H-4-Sthienyl); 7.12 (dd, 1H, *J*_{3,4} = 3.6 Hz, *J*_{3,5} = 1.3 Hz, H-3-Sthienyl); 7.47 (dd, 1H, *J*_{5,4} = 5.3 Hz, *J*_{5,3} = 1.3 Hz, H-5-Sthienyl); 7.94 (s, 1H, H-6); 8.64 (s, 1H, H-2); 12.55 (vbs, 1H, NH). ¹³C NMR (125.7 MHz, DMSO-*d*₆): 21.54 (CH₃-4); 103.13 (C-5); 116.39 (C-4a); 128.08 (CH-4-Sthienyl); 128.37 (CH-5-Sthienyl); 128.77 (CH-3-Sthienyl); 133.34 (CH-6); 138.22 (C-2-Sthienyl); 151.72 (C-7a); 151.74 (CH-2); 159.23 (C-4). IR (KBr): 3075, 2962, 2803, 2773, 2753, 2702, 2576, 1598, 2574, 1434, 1410, 1338, 1132, 1006, 696, 626. HRMS (ESI) calculated for C₁₁H₁₀N₃S₂: 248.0311; found: 248.0311.


**4-Methyl-5-(phenylsulfanyl)-7-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine
(6-methyl-7-(phenylsulfanyl)-9-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-7-deazapurine) (3d)**



Nucleoside **3a** (706 mg, 1 mmol), Me₃Al (1.5 mL, 3 equiv, 2 M in toluene) and 20 mL THF were used according to the general procedure. Crude product was purified using HPFC (hexane/EtOAc, 0–20% EtOAc) and product **3d** was obtained as white foam (380 mg, 55%).

M.p. 61 °C. ¹H NMR (500 MHz, CDCl₃): 2.69 (s, 3H, CH₃); 4.71 (dd, 1H, *J*_{gem} = 12.2 Hz, *J*_{5'a,4'} = 3.9 Hz, H-5'a); 4.81 (bdt, 1H, *J*_{4',3'} = 4.7 Hz, *J*_{4',5'a} = *J*_{4',5'b} = 3.6 Hz, H-4'); 4.89 (dd, 1H, *J*_{gem} = 12.2 Hz, *J*_{5'b,4'} = 3.2 Hz, H-5'b); 6.16 (dd, 1H, *J*_{3',2'} = 5.9 Hz, *J*_{3',4'} = 4.7 Hz, H-3'); 6.24 (t, 1H, *J*_{2',1'} = *J*_{2',3'} = 5.7 Hz, H-2'); 6.71 (d, 1H, *J*_{1',2'} = 5.5 Hz, H-1'); 7.05 (m, 2H, H-*o*-SPh); 7.11 (m, 1H, H-*p*-SPh); 7.20 (m, 2H, H-*m*-SPh); 7.37, 7.40 and 7.41 (3×m, 3×2H, H-*m*-Bz); 7.53, 7.55 and 7.58 (3×m, 3×1H, H-*p*-Bz); 7.61 (s, 1H, H-6); 7.94, 8.01 and 8.07 (3×m, 3×2H, H-*o*-Bz); 8.73 (s, 1H, H-2). ¹³C NMR (125.7 MHz, CDCl₃): 21.24 (CH₃); 63.59 (CH₂-5'); 71.50 (CH-3'); 74.10 (CH-2'); 80.44 (CH-4'); 86.71 (CH-1'); 104.19 (C-5); 118.59 (C-4a); 125.56 (CH-*p*-SPh); 126.14 (CH-*o*-SPh); 128.50 (CH-*m*-Bz); 128.52 (C-*i*-Bz); 128.54 and 128.64 (CH-*m*-Bz); 128.877 (C-*i*-Bz); 129.09 (CH-*m*-SPh); 129.31 (C-*i*-Bz); 129.69, 129.84 and 129.86 (CH-*o*-Bz); 132.14 (CH-6); 133.43, 133.71 and 133.73 (CH-*p*-Bz); 138.34 (C-*i*-SPh); 151.82 (C-7a); 152.28 (CH-2); 161.52 (C-4); 165.09, 165.38 and 166.17 (CO-Bz). IR (KBr): 3058, 3028, 3007, 2956, 2926, 2869, 2854, 1730, 1571, 1449, 1263, 1120, 1096, 1069, 1027, 707. HRMS (ESI) calculated for C₃₉H₃₂O₇N₃S: 686.1956; found: 686.1958.

**4-Methyl-5-[(thiophen-2-yl)sulfanyl]-7-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine
(6-methyl-7-[(thiophen-2-yl)sulfanyl]-9-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)-7-deazapurine) (**4d**)**



Nucleoside **4a** (712 mg, 1 mmol), Me₃Al (1.5 mL, 3 equiv, 2 M in toluene) and 20 mL THF were used according to the general procedure. Crude product was purified using HPFC (DCM/MeOH, 0–5% MeOH) and product **4d** was obtained as white foam (469 mg, 67%).


M.p. 59 °C. ¹H NMR (500 MHz, CDCl₃): 2.92 (s, 3H, CH₃); 4.69 (dd, 1H, *J*_{gem} = 12.2 Hz, *J*_{5'a,4'} = 3.9 Hz, H-5'a); 4.79 (m, 1H, H-4'); 4.87 (dd, 1H, *J*_{gem} = 12.2 Hz, *J*_{5'b,4'} = 3.2 Hz, H-5'b); 6.15 (dd, 1H, *J*_{3',2'} = 5.9 Hz, *J*_{3',4'} = 4.5 Hz, H-3'); 6.21 (t, 1H, *J*_{2',1'} = *J*_{2',3'} = 5.7 Hz, H-2'); 6.68 (d, 1H, *J*_{1',2'} = 5.5 Hz, H-1'); 6.88 (dd, 1H, *J*_{4,5} = 5.3 Hz, *J*_{4,3} = 3.6 Hz, H-4-Sthienyl); 6.99 (dd, 1H, *J*_{3,4} = 3.6 Hz, *J*_{3,5} = 1.3 Hz, H-3-Sthienyl); 7.20 (dd, 1H, *J*_{5,4} = 5.3 Hz, *J*_{5,3} = 1.3 Hz, H-5-Sthienyl); 7.36, 7.40 and 7.47 (3×m, 3×2H, H-*m*-Bz); 7.53 (s, 1H, H-6); 7.51 – 7.62 (m, 3H, H-*p*-Bz); 7.93, 7.99 and 8.12 (3×m, 3×2H, H-*o*-Bz); 8.72 (s, 1H, H-2). ¹³C NMR (125.7 MHz, CDCl₃): 21.94 (CH₃); 63.71 (CH₂-5'); 71.51 (CH-3'); 74.05 (CH-2'); 80.43 (CH-4'); 86.60 (CH-1'); 108.20 (C-5); 118.00 (C-4a); 127.51 (CH-4-Sthienyl); 128.19 (CH-5-Sthienyl); 128.46 and 128.52 (CH-*m*-Bz); 128.56 (C-*i*-Bz); 128.67 (CH-*m*-Bz); 128.80 and 129.41 (C-*i*-Bz); 129.76, 129.83 and 129.85 (CH-*o*-Bz); 130.06 (CH-6); 130.34 (CH-3-Sthienyl); 133.44 and 133.67 (CH-*p*-Bz); 136.26 (C-2-Sthienyl); 151.38 (C-7a); 152.18 (CH-2); 161.21 (C-4); 165.07, 165.36 and 166.15 (CO-Bz). IR (KBr): 3111, 3066, 3028, 3007,

2932, 2851, 1730, 1568, 1452, 1317, 1269, 1177, 1123, 1093, 1069, 1024, 713. HRMS (ESI) calculated for $C_{37}H_{30}O_7N_3S_2$: 692.1520; found: 692.1521.

General procedure for dimethylation

Dimethylamine (3 equiv, 2 M in THF) was added to solution of compound **1a-4a** (1 equiv), in propan-2-ol (25 mL) and the reaction mixture was stirred at 70 °C for 24 h. Volatiles were removed under reduced pressure and crude product was purified by HPFC.


4-(*N,N*-Dimethylamino)-5-(phenylsulfanyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine (6-(*N,N*-Dimethylamino)-7-(phenylsulfanyl)-7-deazapurine) (**1e**)



Deazapurine **1a** (523 mg, 2 mmol) was used according to the general procedure. Crude product was purified using HPFC (hexane/EtOAc, 0–50% EtOAc) and product **1e** was obtained as yellowish solid (454 mg, 84%). Crystallization in ethanol/H₂O gave white needles.

M.p. 201 °C. ¹H NMR (600.1 MHz, DMSO-*d*₆): 3.11 (s, 6H, (CH₃)₂N); 7.00 (m, 2H, H-*o*-Ph); 7.09 (m, 1H, H-*p*-Ph); 7.23 (m, 2H, H-*m*-Ph); 7.66 (s, 1H, H-6); 8.21 (s, 1H, H-2); 12.36 (bs, 1H, NH). ¹³C NMR (150.9 MHz, DMSO-*d*₆): 41.23 ((CH₃)₂N); 98.32 (C-5); 104.52 (C-4a); 125.15 (CH-*o*-Ph); 125.21 (CH-*p*-Ph); 129.22 (CH-*m*-Ph); 131.94 (CH-6); 140.13 (C-*i*-Ph); 150.85 (CH-2); 153.58 (C-7a); 159.41 (C-4). IR (KBr): 3090, 2968, 2863, 2818, 1589, 1559, 1488, 1416, 1398, 1063, 922, 860 743. HRMS (ESI) calculated for C₁₄H₁₅N₄S: 271.1012; found: 271.1012. Anal. calculated for: C₁₄H₁₄N₄S: C, 62.20; H, 5.22; N, 20.72; S, 11.86; found: C, 61.97; H, 5.18; N, 20.64; S, 11.73.


**4-(*N,N*-Dimethylamino)-5-[(thiophen-2-yl)sulfanyl]-7*H*-pyrrolo[2,3-*d*]pyrimidine
(6-(*N,N*-Dimethylamino)-7-[(thiophen-2-yl)sulfanyl]-7-deazapurine) (2e)**



Deazapurine **2a** (535 mg, 2 mmol) was used according to the general procedure. Crude product was purified using HPFC (EtOAc/MeOH, 0–5% MeOH) and product **2e** was obtained as brownish solid (346 mg, 63%).

M.p. 185 °C. ^1H NMR (401 MHz, DMSO- d_6): 3.22 (s, 6H, $(\text{CH}_3)_2\text{N}$); 6.95 (dd, 1H, $J_{4,5} = 5.3$ Hz, $J_{4,3} = 3.6$ Hz, H-4-Sthienyl); 7.07 (dd, 1H, $J_{3,4} = 3.6$ Hz, $J_{3,5} = 1.3$ Hz, H-3-Sthienyl); 7.44 (dd, 1H, $J_{5,4} = 5.3$ Hz, $J_{5,3} = 1.3$ Hz, H-5-Sthienyl); 7.62 (s, 1H, H-6); 8.19 (s, 1H, H-2); 12.23 (bs, 1H, NH). ^{13}C NMR (100.8 MHz, DMSO- d_6): 41.45 ($(\text{CH}_3)_2\text{N}$); 103.09 (C-5); 103.91 (C-4a); 127.95 (CH-4-Sthienyl); 128.47 (CH-5-Sthienyl); 129.14 (CH-3-Sthienyl); 130.17 (CH-6); 138.47 (C-2-Sthienyl); 150.82 (CH-2); 153.12 (C-7a); 159.48 (C-4). IR (KBr): 3081, 2941, 2860, 2806, 1589, 1559, 1416, 1401, 1060, 928, 848, 692. HRMS (ESI) calculated for $\text{C}_{12}\text{H}_{13}\text{N}_4\text{S}_2$: 277.0576; found: 277.0576.


**4-(*N,N*-Dimethylamino)-5-(phenylsulfanyl)-7-(2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine
(6-(*N,N*-Dimethylamino)-7-(phenylsulfanyl)-9-(2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyl)-7-deazapurine) (3e)**



Nucleoside **3a** (706 mg, 1 mmol) was used according to the general procedure. Crude product was purified using HPFC (hexane/EtOAc, 0–20% EtOAc) and product **3e** was obtained as white foam (624 mg, 88%).

M.p. 67 °C. ^1H NMR (500 MHz, CDCl_3): 3.17 (s, 6H, $(\text{CH}_3)_2\text{N}$); 4.70 (dd, 1H, $J_{\text{gem}} = 12.1$ Hz, $J_{5'a,4'} = 3.8$ Hz, H-5'a); 4.78 (bdt, 1H, $J_{4',3'} = 4.6$ Hz, $J_{4',5'a} = J_{4',5'b} = 3.5$ Hz, H-4'); 4.85 (dd, 1H, $J_{\text{gem}} = 12.1$ Hz, $J_{5'b,4'} = 3.2$ Hz, H-5'b); 6.11 (dd, 1H, $J_{3',2'} = 5.9$ Hz, $J_{3',4'} = 4.6$ Hz, H-3'); 6.18 (t, 1H, $J_{2',1'} = J_{2',3'} = 5.8$ Hz, H-2'); 6.75 (d, 1H, $J_{1',2'} = 5.6$ Hz, H-1'); 7.01 (m, 2H, H-*o*-SPh); 7.08 (m, 1H, H-*p*-SPh); 7.17 (m, 2H, H-*m*-SPh); 7.33 – 7.42 (m, 6H, CH-*m*-Bz); 7.45 (s, 1H, H-6); 7.48 – 7.60 (m, 3H, H-*p*-Bz); 7.95, 7.98 and 8.08 (3×m, 3×2H, H-*o*-Bz); 8.33 (s, 1H, H-2). ^{13}C NMR (125.7 MHz, CDCl_3): 41.17 ($(\text{CH}_3)_2\text{N}$); 63.54 (CH_2 -5'); 71.32 (CH-3'); 73.79 (CH-2'); 80.03 (CH-4'); 85.94 (CH-1'); 102.88 (C-5); 105.52 (C-4a); 125.21 (CH-*p*-SPh); 125.70 (CH-*o*-SPh); 128.44, 128.48 and 128.58 (CH-*m*-Bz); 128.64 and 128.81 (C-*i*-Bz); 128.88 (CH-*m*-SPh); 129.35 (CH-6); 129.67, 129.83 and 129.88 (CH-*o*-Bz); 133.30 and 133.61 (CH-*p*-Bz); 138.79 (C-*i*-SPh); 151.13 (CH-2); 152.95 (C-7a); 159.55 (C-4); 164.83, 165.14 and 165.94 (CO-Bz). IR (KBr): 3123, 3058, 3031, 3010, 2950, 2926, 2881, 2806, 1727, 1565, 1544, 1455, 1419, 1401, 1317, 1263, 1126, 1096, 1072, 1027, 707.. HRMS (ESI) calculated for $\text{C}_{40}\text{H}_{35}\text{O}_7\text{N}_4\text{S}$: 715.2221; found: 715.2223.

4-(*N,N*-Dimethylamino)-5-[(thiophen-2-yl)sulfanyl]-7-(2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine
(6-(*N,N*-Dimethylamino)-7-[(thiophen-2-yl)sulfanyl]-9-(2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyl)-7-deazapurine) (4e)



Nucleoside **4a** (712 mg, 1 mmol) was used according to the general procedure. Crude product was purified using HPFC (DCM/MeOH, 0–5% MeOH) and product **4e** was obtained as white foam (634 mg, 88%).


M.p. 81 °C. ^1H NMR (500 MHz, CDCl_3): 3.29 (s, 6H, $(\text{CH}_3)_2\text{N}$); 4.67 (dd, 1H, $J_{\text{gem}} = 12.1$ Hz, $J_{5'a,4'} = 3.9$ Hz, H-5'a); 4.75 (m, 1H, H-4'); 4.82 (dd, 1H, $J_{\text{gem}} = 12.1$ Hz, $J_{5'b,4'} = 3.2$ Hz, H-5'b); 6.09 (dd, 1H, $J_{3',2'} = 5.8$ Hz, $J_{3',4'} = 4.4$ Hz, H-3'); 6.15 (t, 1H, $J_{2',1'} = J_{2',3'} = 5.8$ Hz, H-2'); 6.70 (d, 1H, $J_{1',2'} = 5.7$ Hz, H-1'); 6.83 (dd, 1H, $J_{4,5} = 5.3$ Hz, $J_{4,3} = 3.6$ Hz, H-4-Sthienyl); 6.93 (dd, 1H, $J_{3,4} = 3.6$ Hz, $J_{3,5} = 1.3$ Hz, H-3-Sthienyl); 7.16 (dd, 1H, $J_{5,4} = 5.3$ Hz, $J_{5,3} = 1.3$ Hz, H-5-Sthienyl); 7.32 (s, 1H, H-6); 7.36, 7.38 and 7.47 (3×m, 3×2H, H-*m*-Bz); 7.53, 7.56 and 7.59 (3×m, 3×1H, H-*p*-Bz); 7.95, 7.96 and 8.14 (3×m, 3×2H, H-*o*-Bz); 8.33 (s, 1H, H-2). ^{13}C NMR (125.7 MHz, CDCl_3): 41.64 ($(\text{CH}_3)_2\text{N}$); 63.94 (CH_2 -5'); 71.55 (CH-3'); 73.98 (CH-2'); 80.23 (CH-4'); 86.05 (CH-1'); 105.34 (C-5); 107.91 (C-4a); 126.92 (CH-6); 127.38 (CH-4-Sthienyl); 128.13 (CH-5-Sthienyl); 128.42, 128.46 and 128.65 (CH-*m*-Bz); 128.70, 128.84 and 129.48 (C-*i*-Bz); 129.79, 129.82 and 129.89 (CH-*o*-Bz); 130.28 (CH-3-Sthienyl); 133.35 and 133.58 (CH-*p*-Bz); 136.59 (C-2-Sthienyl); 151.37 (CH-2); 152.82 (C-7a); 160.04 (C-4); 165.07, 165.37 and 166.18 (CO-Bz). IR (KBr): 3066, 2926, 2887, 2854, 1724, 1562, 1544,

1449, 1407, 1317, 1266, 1123, 1096, 1069, 1024, 710. HRMS (ESI) calculated for $C_{38}H_{33}O_7N_4S_2$: 721.1785; found: 721.1787.

General procedure for methylation

Compound **1a-4a** (1 equiv), aq. methylamine (40% [w/w], 5 mL) in dioxane (5 mL) was stirred at autoclave at 120 °C for 18 h. Solvent was then evaporated under reduced pressure and crude products were purified using RP-HPFC (0→100% of MeOH in H₂O)


4-(*N*-Methylamino)-5-(phenylsulfanyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine (6-(*N*-Methylamino)-7-(phenylsulfanyl)-7-deazapurine) (**1f**)



Reaction of deazapurine **1a** (523 mg, 2 mmol) according to the general procedure afforded compound **1f** as brownish solid (423 mg, 83 %). Crystallization in ethanol/H₂O gave yellowish needles.

M.p. 230 °C. ¹H NMR (500 MHz, DMSO-*d*₆): 2.90 (d, 3H, $J_{CH_3,NH}$ = 4.8 Hz, CH₃NH); 6.48 (q, 1H, J_{NH,CH_3} = 4.8 Hz, CH₃NH); 7.09 (m, 2H, H-*o*-Ph); 7.13 (m, 1H, H-*p*-Ph); 7.26 (m, 2H, H-*m*-Ph); 7.55 (s, 1H, H-6); 8.19 (s, 1H, H-2); 12.19 (vbs, 1H, NH). ¹³C NMR (125.7 MHz, DMSO-*d*₆): 27.62 (CH₃NH); 97.87 (C-5); 103.25 (C-4a); 125.71 (CH-*p*-Ph); 126.02 (CH-*o*-Ph); 129.33 (CH-*m*-Ph); 129.59 (CH-6); 139.07 (C-*i*-Ph); 150.99 (C-7a); 152.67 (CH-2); 157.08 (C-4). IR (KBr): 3374, 3099, 3058, 2962, 2902, 2860, 2812, 1607, 1586, 1491, 1485, 1383, 881, 737. HRMS (ESI) calculated for C₁₃H₁₃N₄S: 257.0855 ; found: 257.0855. Anal. calculated for C₁₃H₁₂N₄S: C, 60.91; H, 4.72; N, 21.86; S, 12.51 ; found: C, 60.66; H, 4.71; N, 21.75; S, 12.17.


**4-(*N*-Methylamino)-5-[(thiophen-2-yl)sulfanyl]-7*H*-pyrrolo[2,3-*d*]pyrimidine
(6-(*N*-Methylamino)-7-[(thiophen-2-yl)sulfanyl]-7-deazapurine) (2f)**



Reaction of deazapurine **2a** (535 mg, 2 mmol) according to the general procedure afforded compound **2f** as brownish solid (303 mg, 58 %).

M.p. 212 °C. ¹H NMR (401 MHz, DMSO-*d*₆): 3.01 (d, 3H, *J*_{CH₃,NH} = 4.8 Hz, CH₃NH); 6.71 (q, 1H, *J*_{NH,CH₃} = 4.8 Hz, CH₃NH); 6.97 (dd, 1H, *J*_{4,5} = 5.3 Hz, *J*_{4,3} = 3.6 Hz, H-4-Sthienyl); 7.24 (dd, 1H, *J*_{3,4} = 3.6 Hz, *J*_{3,5} = 1.3 Hz, H-3-Sthienyl); 7.49 (dd, 1H, *J*_{5,4} = 5.3 Hz, *J*_{5,3} = 1.3 Hz, H-5-Sthienyl); 7.54 (s, 1H, H-6); 8.17 (s, 1H, H-2); 12.10 (bs, 1H, NH). ¹³C NMR (100.8 MHz, DMSO-*d*₆): 27.74 (CH₃NH); 102.26 (C-5); 102.53 (C-4a); 127.97 (CH-4-Sthienyl); 128.50 (CH-6); 129.19 (CH-5-Sthienyl); 129.92 (CH-3-Sthienyl); 137.86 (C-2-Sthienyl); 150.46 (C-7a); 152.43 (CH-2); 156.76 (C-4). IR (KBr): 3392, 3102, 3060, 2995, 2965, 2905, 2863, 2788, 1607, 1595, 1488, 1413, 1383, 1350, 1314, 881, 626. HRMS (ESI) calculated for C₁₁H₁₁N₄S₂: 263.0420 ; found: 263.0420.


**4-(*N*-Methylamino)-5-(phenylsulfanyl)-7-β-D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine
(6-(*N*-Methylamino)-7-(phenylsulfanyl)-9-β-D-ribofuranosyl)-7-deazapurine) (3f)**



Reaction of nucleoside **3a** (706 mg, 1 mmol) according to the general procedure afforded compound **3f** as white solid (352 mg, 90 %). Crystallization in MeOH/H₂O gave white foam.

M.p. 157 °C. $[\alpha]_D -57.9$ (0.21). ^1H NMR (600.1 MHz, DMSO- d_6): 2.91 (d, 3H, $J_{\text{CH}_3,\text{NH}} = 4.8$ Hz, CH_3NH); 3.55 (ddd, 1H, $J_{\text{gem}} = 12.0$ Hz, $J_{5'a,\text{OH}} = 6.2$ Hz, $J_{5'a,4'} = 3.7$ Hz, H-5'a); 3.65 (ddd, 1H, $J_{\text{gem}} = 12.0$ Hz, $J_{5'b,\text{OH}} = 5.0$ Hz, $J_{5'b,4'} = 3.7$ Hz, H-5'b); 3.92 (q, 1H, $J_{4',5'a} = J_{4',5'b} = J_{4',3'} = 3.5$ Hz, H-4'); 4.10 (td, 1H, $J_{3',2'} = J_{3',\text{OH}} = 5.0$ Hz, $J_{3',4'} = 3.2$ Hz, H-3'); 4.43 (td, 1H, $J_{2',1'} = J_{2',\text{OH}} = 6.2$ Hz, $J_{2',3'} = 5.1$ Hz, H-2'); 5.14 (d, 1H, $J_{\text{OH},3'} = 4.9$ Hz, OH-3'); 5.21 (dd, 1H, $J_{\text{OH},5'a} = 6.2$ Hz, $J_{\text{OH},5'b} = 5.0$ Hz, OH-5'); 5.37 (d, 1H, $J_{\text{OH},2'} = 6.3$ Hz, OH-2'); 6.08 (d, 1H, $J_{1',2'} = 6.0$ Hz, H-1'); 6.59 (q, 1H, $J_{\text{NH},\text{CH}_3} = 4.8$ Hz, CH_3NH); 7.13 (m, 2H, H-*o*-SPh); 7.16 (m, 1H, H-*p*-SPh); 7.29 (m, 2H, H-*m*-SPh); 7.87 (s, 1H, H-6); 8.23 (s, 1H, H-2). ^{13}C NMR (150.9 MHz, DMSO- d_6): 27.74 (CH_3NH); 61.65 (CH_2 -5'); 70.63 (CH-3'); 74.25 (CH-2'); 85.46 (CH-4'); 87.63 (CH-1'); 99.16 (C-5); 103.82 (C-4a); 125.95 (CH-*p*-SPh); 126.24 (CH-*o*-SPh); 129.44 (CH-*m*-SPh); 129.96 (CH-6); 138.39 (C-*i*-SPh); 150.33 (C-7a); 152.62 (CH-2); 157.10 (C-4). IR (KBr): 3398, 3180, 3126, 2941, 2917, 2905, 2896, 2866, 1613, 1562, 1488, 1389, 1099, 1060, 740, 629. HRMS (ESI) calculated for $\text{C}_{18}\text{H}_{21}\text{O}_4\text{N}_4\text{S}$: 389.1278; found: 389.1281. Anal. calculated for $\text{C}_{18}\text{H}_{20}\text{N}_4\text{O}_4\text{S} \cdot 1.25\text{H}_2\text{O}$: C, 52.61; H, 5.52; N, 13.63; S, 7.8; found: C, 52.79; H, 5.35; N, 13.46; S, 7.98.

**4-(*N*-Methylamino)-5-[(thiophen-2-yl)sulfanyl]-7- β -D-ribofuranosyl)-pyrrolo[2,3-
d]pyrimidine
(6-(*N*-Methylamino)-7-[(thiophen-2-yl)sulfanyl]-9- β -D-ribofuranosyl)-7-deazapurine)
(4f)**



Reaction of nucleoside **4a** (712 mg, 1 mmol) according to the general procedure afforded compound **4f** as white solid (297 mg, 75 %).


M.p. 187 °C. $[\alpha]_D -51.7$ (0.23). ^1H NMR (401.0 MHz, DMSO- d_6): 3.03 (d, 3H, $J_{\text{CH}_3,\text{NH}} = 4.8$ Hz, CH_3NH); 3.54 (dd, 1H, $J_{\text{gem}} = 12.0$ Hz, $J_{5'a,4'} = 3.7$ Hz, H-5'a); 3.65 (dd, 1H, $J_{\text{gem}} = 12.0$ Hz, $J_{5'b,4'} = 3.7$ Hz, H-5'b); 3.91 (q, 1H, $J_{4',5'a} = J_{4',5'b} = J_{4',3'} = 3.6$ Hz, H-4'); 4.09 (dd, 1H, $J_{3',2'} = 5.1$ Hz, $J_{3',4'} = 3.4$ Hz, H-3'); 4.39 (dd, 1H, $J_{2',1'} = 6.0$ Hz, $J_{2',3'} = 5.1$ Hz, H-2'); 5.02 – 5.50 (m, 3H, OH-2',3',5'); 6.03 (d, 1H, $J_{1',2'} = 6.0$ Hz, H-1'); 6.80 (q, 1H, $J_{\text{NH},\text{CH}_3} = 4.8$ Hz, CH_3NH); 6.99 (dd, 1H, $J_{4,5} = 5.3$ Hz, $J_{4,3} = 3.6$ Hz, H-4-Sthienyl); 7.27 (dd, 1H, $J_{3,4} = 3.6$ Hz, $J_{3,5} = 1.3$ Hz, H-3-Sthienyl); 7.53 (dd, 1H, $J_{5,4} = 5.3$ Hz, $J_{5,3} = 1.3$ Hz, H-5-Sthienyl); 7.87 (s, 1H, H-6); 8.20 (s, 1H, H-2). ^{13}C NMR (100.8 MHz, DMSO- d_6): 27.80 (CH_3NH); 61.68 (CH_2 -5'); 70.61 (CH -3'); 74.20 (CH -2'); 85.47 (CH -4'); 87.66 (CH -1'); 103.17 and 103.33 (C-4a,5); 128.04 (CH -4-Sthienyl); 128.87 (CH -6); 129.62 (CH -5-Sthienyl); 130.57 (CH -3-Sthienyl); 136.89 (C-2-Sthienyl); 149.88 (C-7a); 152.59 (CH -2); 156.95 (C-4). IR (KBr): 3503, 3404, 3279, 3126, 3099, 2929, 2869, 1613, 1568, 1491, 1416, 1398, 1338, 1308, 1126, 1084, 1048, 701. HRMS (ESI) calculated for $\text{C}_{16}\text{H}_{19}\text{O}_4\text{N}_4\text{S}_2$: 395.0842; found: 395.0842.

General procedure for amination

Compound **1a-4a** (1 equiv), aq ammonia (25% [w/w], 5 mL) in dioxane (5 mL) was stirred at autoclave at 120 °C for 18h. After cooling to rt precipitate was formed and filtered off.

4-Amino-5-(phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine

(6-Amino-7-(phenylsulfanyl)-7-deazapurine) (**1g**)




Reaction of deazapurine **1a** (523 mg, 2 mmol) according to the general procedure afforded compound **1g** (411 mg, 85%) as white powder.

^1H NMR was compared with published data¹.

4-Amino-5-[(thiophen-2-yl)sulfanyl]-7H-pyrrolo[2,3-d]pyrimidine


(6-Amino-7-[(thiophen-2-yl)sulfanyl]-7-deazapurine) (2g)



Reaction of deazapurine **2a** (535 mg, 2 mmol) according to the general procedure afforded compound **2g** (425 mg, 85%) as white powder.

M.p. 281 °C. ^1H NMR (500 MHz, DMSO- d_6): 6.70 (bs, 2H, NH_2); 6.97 (dd, 1H, $J_{4,5} = 5.3$ Hz, $J_{4,3} = 3.6$ Hz, H-4-Sthienyl); 7.20 (dd, 1H, $J_{3,4} = 3.6$ Hz, $J_{3,5} = 1.3$ Hz, H-3-Sthienyl); 7.49 (dd, 1H, $J_{5,4} = 5.3$ Hz, $J_{5,3} = 1.3$ Hz, H-5-Sthienyl); 7.57 (s, 1H, H-6); 8.08 (s, 1H, H-2); 12.01 (vbs, 1H, NH). ^{13}C NMR (125.7 MHz, DMSO- d_6): 102.18 and 102.22 (C-5,4a); 128.00 (CH-4-Sthienyl); 128.84 (CH-6); 128.88 (CH-5-Sthienyl); 129.35 (CH-3-Sthienyl); 137.99 (C-2-Sthienyl); 151.42 (C-7a); 152.76 (CH-2); 157.43 (C-4). IR (KBr): 3099, 3069, 2980, 2806, 2672, 1643, 1583, 1320, 719, 686. HRMS (ESI) calculated for $\text{C}_{10}\text{H}_9\text{N}_4\text{S}_2$: 249.0263; found: 249.0264.


**4-Amino-5-(phenylsulfanyl)-7- β -D-ribofuranosyl-pyrrolo[2,3-*d*]pyrimidine
(6-amino-7-(phenylsulfanyl)-9- β -D-ribofuranosyl)-7-deazapurine) (3g)**



Reaction of nucleoside **3a** (706 mg, 1 mmol) according to the general procedure afforded compound **3g** (321 mg, 86%) as white powder.

M.p. 214 °C. $[\alpha]_D -62.8$ (0.21). ^1H NMR (600.1 MHz, DMSO- d_6): 3.55 (ddd, 1H, $J_{gem} = 12.0$ Hz, $J_{5'a,OH} = 6.2$ Hz, $J_{5'a,4'} = 3.7$ Hz, H-5'a); 3.65 (ddd, 1H, $J_{gem} = 12.0$ Hz, $J_{5'b,OH} = 5.0$ Hz, $J_{5'b,4'} = 3.7$ Hz, H-5'b); 3.93 (q, 1H, $J_{4',5'a} = J_{4',5'b} = J_{4',3'} = 3.6$ Hz, H-4'); 4.11 (td, 1H, $J_{3',2'} = J_{3',OH} = 4.9$ Hz, $J_{3',4'} = 3.3$ Hz, H-3'); 4.34 (td, 1H, $J_{2',1'} = J_{2',OH} = 6.2$ Hz, $J_{2',3'} = 5.1$ Hz, H-2'); 5.15 (d, 1H, $J_{OH,3'} = 4.8$ Hz, OH-3'); 5.22 (dd, 1H, $J_{OH,5'a} = 6.3$ Hz, $J_{OH,5'b} = 5.0$ Hz, OH-5'); 5.39 (d, 1H, $J_{OH,2'} = 6.3$ Hz, OH-2'); 6.09 (d, 1H, $J_{1',2'} = 6.1$ Hz, H-1'); 7.12 (m, 2H, H-*o*-SPh); 7.16 (m, 1H, H-*p*-SPh); 7.29 (m, 2H, H-*m*-SPh); 7.90 (s, 1H, H-6); 8.14 (s, 1H, H-2). ^{13}C NMR (150.9 MHz, DMSO- d_6): 61.67 (CH₂-5'); 70.67 (CH-3'); 74.23 (CH-2'); 85.49 (CH-4'); 87.58 (CH-1'); 99.34 (C-5); 103.39 (C-4a); 125.94 (CH-*p*-SPh); 126.01 (CH-*o*-SPh); 129.50 (CH-*m*-SPh); 130.28 (CH-6); 138.29 (C-*i*-SPh); 151.21 (C-7a); 152.77 (CH-2); 157.65 (C-4). IR (KBr): 3407, 3282, 3147, 3087, 1646, 1586, 1556, 1473, 1440, 1329, 1317, 1144, 1015, 749. HRMS (ESI) calculated for C₁₇H₁₉O₄N₄S: 375.1122; found: 375.1123. Anal. calculated for: C₁₇H₁₈N₄O₄S·0.60H₂O: C, 53; H, 5.02; N, 14.54; S, 8.32; found: C, 52.77; H, 4.72; N, 14.29; S, 8.54.

4-Amino-5-[(thiophen-2-yl)sulfanyl]-7-β-D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine (6-amino-7-[(thiophen-2-yl)sulfanyl]-9-β-D-ribofuranosyl)-7-deazapurine) (4g)




Reaction of nucleoside **4a** (712 mg, 1 mmol) according to the general procedure. Precipitate was not formed. Solvent was then evaporated under reduced pressure and crude products were purified using RP-HPFC (0→100% of MeOH in H₂O) and product **4g** was obtained as white powder (267 mg, 70 %).

M.p. 178 °C. $[\alpha]_D -49.5$ (0.23). ^1H NMR (401.0 MHz, DMSO- d_6): 3.55 (ddd, 1H, $J_{gem} = 12.0$ Hz, $J_{5'a,OH} = 6.2$ Hz, $J_{5'a,4'} = 3.7$ Hz, H-5'a); 3.65 (ddd, 1H, $J_{gem} = 12.0$ Hz, $J_{5'b,OH} = 4.9$ Hz, $J_{5'b,4'} = 3.7$ Hz, H-5'b); 3.91 (bq, 1H, $J_{4',5'a} = J_{4',5'b} = J_{4',3'} = 3.5$ Hz, H-4'); 4.09 (td, 1H, $J_{3',2'} = J_{3',OH} = 4.9$ Hz, $J_{3',4'} = 3.3$ Hz, H-3'); 4.40 (td, 1H, $J_{2',1'} = J_{2',OH} = 6.2$ Hz, $J_{2',3'} = 5.1$ Hz, H-2'); 5.13 (d, 1H, $J_{OH,3'} = 4.8$ Hz, OH-3'); 5.23 (dd, 1H, $J_{OH,5'a} = 6.2$ Hz, $J_{OH,5'b} = 4.9$ Hz, OH-5'); 5.35 (d, 1H, $J_{OH,2'} = 6.4$ Hz, OH-2'); 6.03 (d, 1H, $J_{1',2'} = 6.1$ Hz, H-1'); 6.88 (vbs, 2H, NH_2); 6.99 (dd, 1H, $J_{4,5} = 5.3$ Hz, $J_{4,3} = 3.6$ Hz, H-4-Sthienyl); 7.24 (dd, 1H, $J_{3,4} = 3.6$ Hz, $J_{3,5} = 1.3$ Hz, H-3-Sthienyl); 7.53 (dd, 1H, $J_{5,4} = 5.3$ Hz, $J_{5,3} = 1.3$ Hz, H-5-Sthienyl); 7.90 (s, 1H, H-6); 8.11 (s, 1H, H-2). ^{13}C NMR (100.8 MHz, DMSO- d_6): 61.68 (CH_2 -5'); 70.63 (CH -3'); 74.17 (CH -2'); 85.47 (CH -4'); 87.60 (CH -1'); 102.77 (C-4a); 103.45 (C-5); 128.09 (CH -4-Sthienyl); 129.23 (CH -6); 129.37 (CH -5-Sthienyl); 130.10 (CH -3-Sthienyl); 136.95 (C-2-Sthienyl); 150.74 (C-7a); 152.70 (CH -2); 157.58 (C-4). IR (KBr): 3285, 3102, 1625, 1589, 1556, 1479, 1437, 1344, 1311, 1129, 1045, 701. HRMS (ESI) calculated for $\text{C}_{15}\text{H}_{17}\text{O}_4\text{N}_4\text{S}_2$: 381.0686; found: 381.0687.

Methoxylation

4-Chloro-5-(phenylsulfanyl)-7-{([2-(trimethylsilyl)ethoxy]methyl)-7H-pyrrolo[2,3-d]pyrimidine

(6-chloro-7-(phenylsulfanyl)-9-{([2-(trimethylsilyl)ethoxy]methyl)-7-deazapurine) (5a)




A mixture of **1a** (1.044 g, 4 mmol) and DMF (10 mL) was cooled to -5 °C in an ice/brine bath. Sodium hydride (NaH, 60 wt%, 178 mg, 4.4 mmol, 1.1 equiv) was added in portions as a solid under stirring. The solution darkened over 15 minutes. 2-(Trimethylsilyl)ethoxymethyl chloride (SEM-Cl, 0.78 mL, 4.4 mmol, 1.1 equiv) was added

slowly via syringe so that the temperature did not exceed 5 °C. The reaction was stirred for 30 minutes to completion (monitored by TLC). Water (25 mL) was slowly added to quench the reaction. The mixture was then diluted with water (100 mL) and ether (200 mL). The layers were separated and the aqueous layer was extracted with ether (200 mL). The combined organic layers were washed with water (2 x 100 mL) and brine (100 mL), dried over sodium sulfate (Na₂SO₄), and concentrated under the reduced pressure. Crude product was purified using by HPFC (hexane/EtOAc, 0–20% EtOAc) and product **5a** (1.25 g, 80%) was obtained as a pale yellow oil which solidified upon standing at room temperature.

M.p. 107 °C. ¹H NMR (500 MHz, CDCl₃): -0.04 (s, 9H, CH₃Si); 0.93 (m, 2H, OCH₂CH₂Si); 3.57 (m, 2H, OCH₂CH₂Si); 5.67 (s, 2H, NCH₂O); 7.13 – 7.18 (m, 3H, H-*o,p*-SPh); 7.23 (m, 2H, H-*m*-SPh); 7.60 (s, 1H, H-6); 8.68 (bs, 1H, H-2). ¹³C NMR (125.7 MHz, CDCl₃): -1.46 (CH₃Si); 17.74 (OCH₂CH₂Si); 67.15 (OCH₂CH₂Si); 73.38 (NCH₂O); 104.42 (C-5); 116.9 (C-4a); 125.95 (CH-*p*-SPh); 127.25 (CH-*o*-SPh); 129.02 (CH-*m*-SPh); 134.96 (CH-6); 137.86 (C-*i*-SPh); 151.84 (CH-2); 152.82 (C-7a); 153.01 (C-4). IR (KBr): 3060, 3004, 2953, 2923, 1586, 1541, 1452, 1368, 1335, 1248, 1227, 1090, 979, 863, 830, 734, 629. HRMS (ESI) calculated for C₁₈H₂₃ON₃ClSSi: 392.1014; found: 392.1015.

**4-Chloro-5-[(thiophen-2-yl)sulfanyl]-7-{([2-(trimethylsilyl)ethoxy]methyl)-7H-pyrrolo[2,3-*d*]pyrimidine
(6-chloro-7-[(thiophen-2-yl)sulfanyl]-9-{([2-(trimethylsilyl)ethoxy]methyl)-7-deazapurine) (**6a**)**




Compound **6a** was prepared as described for **5a** from 6-chloro-7-[(thiophen-2-yl)sulfanyl]-7-deazapurine (**2a**) (1.107 g, 4 mmol) to give protected deazapurine **6a** (1.09 g, 69%) as a pale yellow oil which solidified upon standing at room temperature.

M.p. 57°C. ^1H NMR (500 MHz, CDCl_3): -0.06 (s, 9H, CH_3Si); 0.89 (m, 2H, $\text{OCH}_2\text{CH}_2\text{Si}$); 3.51 (m, 2H, $\text{OCH}_2\text{CH}_2\text{Si}$); 5.60 (s, 2H, NCH_2O); 6.97 (dd, 1H, $J_{4,5} = 5.3$ Hz, $J_{4,3} = 3.6$ Hz, H-4-Sthienyl); 7.26 (dd, 1H, $J_{3,4} = 3.6$ Hz, $J_{3,5} = 1.3$ Hz, H-3-Sthienyl); 7.33 (dd, 1H, $J_{5,4} = 5.3$ Hz, $J_{5,3} = 1.3$ Hz, H-5-Sthienyl); 7.41 (s, 1H, H-6); 8.65 (s, 1H, H-2). ^{13}C NMR (125.7 MHz, CDCl_3): -1.48 (CH_3Si); 17.68 ($\text{OCH}_2\text{CH}_2\text{Si}$); 67.03 ($\text{OCH}_2\text{CH}_2\text{Si}$); 73.26 (NCH_2O); 108.87 (C-5); 116.09 (C-4a); 127.64 (CH-4-Sthienyl); 129.44 (CH-5-Sthienyl); 132.25 (CH-6); 132.49 (CH-3-Sthienyl); 134.53 (C-2-Sthienyl); 151.65 (CH-2); 152.30 (C-7a); 152.66 (C-4). IR (KBr): 3090, 3060, 2950, 2896, 1571, 1538, 1452, 1440, 1422, 1401, 1356, 1332, 1251, 1216, 1180, 1096, 979, 866, 836, 713, 689, 632. HRMS (ESI) calculated for $\text{C}_{16}\text{H}_{21}\text{ON}_3\text{ClS}_2\text{Si}$: 398.0578; found: 398.0579.

4-Methoxy-5-(phenylsulfanyl)-7-([2-(trimethylsilyl)ethoxy]methyl)-7H-pyrrolo[2,3-d]pyrimidine

(6-methoxy-7-(phenylsulfanyl)-9-([2-(trimethylsilyl)ethoxy]methyl)-7-deazapurine) (5h)




Protected deazapurine **5a** (950 mg, 2.5 mmol, 1 equiv) was dissolved in acetone (10 mL) and 1 M solution of MeONa in MeOH (5 mL, 2 equiv) was added. Reaction mixture was stirred at rt overnight. Solvents were evaporated under reduced pressure and the mixture was then diluted with water (25 mL) and EtOAc (25 mL). The layers were separated and the aqueous layer was extracted two times with EtOAc (25 mL). The combined organic layers were dried over sodium sulfate (Na_2SO_4), and concentrated under the reduced pressure to give product **5h** (1.01 g, 99%) as a yellow oil which solidified upon standing at room temperature.

M.p. 286 °C. ^1H NMR (500 MHz, CDCl_3): -0.05 (s, 9H, CH_3Si); 0.91 (m, 2H, $\text{OCH}_2\text{CH}_2\text{Si}$); 3.56 (m, 2H, $\text{OCH}_2\text{CH}_2\text{Si}$); 3.97 (s, 3H, $\text{CH}_3\text{O-4}$); 5.61 (s, 2H, NCH_2O); 7.13 (m, 1H, H-*p*-SPh); 7.19 – 7.24 (m, 4H, H-*o,m*-SPh); 7.33 (s, 1H, H-6); 8.48 (s, 1H, H-2). ^{13}C NMR (125.7 MHz, CDCl_3): -1.47 (CH_3Si); 17.74 ($\text{OCH}_2\text{CH}_2\text{Si}$); 53.75 ($\text{CH}_3\text{O-4}$); 66.69 ($\text{OCH}_2\text{CH}_2\text{Si}$);

73.17 (NCH₂O); 104.00 (C-5); 106.33 (C-4a); 125.72 (CH-*p*-SPh); 127.74 and 128.74 (CH-*m,o*-SPh); 130.67 (CH-6); 138.19 (C-*i*-SPh); 152.11 (CH-2); 153.28 (C-7a); 163.65 (C-4). IR (KBr): 3087, 3052, 2992, 2947, 2935, 2896, 1589, 1562, 1476, 1407, 1338, 1323, 1248, 1222, 1093, 863, 842, 743. HRMS (ESI) calculated for C₁₉H₂₅O₂N₃NaSSi: 410.1329; found: 410.1331.

4-Methoxy-5-[(thiophen-2-yl)sulfanyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-*d*]pyrimidine


(6-methoxy-7-[(thiophen-2-yl)sulfanyl]-9-{[2-(trimethylsilyl)ethoxy]methyl}-7-deazapurine) (6h)



Compound **6h** was prepared as described for **5h** from 6-methoxy-7-[(thiophen-2-yl)sulfanyl]-9-{[2-(trimethylsilyl)ethoxy]methyl}-7-deazapurine (**6a**) (995 mg, 2.5 mmol) to give 6-methoxy deazapurine **6h** (930 mg, 95%) as a pale yellow oil which solidified upon standing at room temperature.

M.p. 101 °C. ¹H NMR (500 MHz, CDCl₃): -0.07 (s, 9H, CH₃Si); 0.88 (m, 2H, OCH₂CH₂Si); 3.50 (m, 2H, OCH₂CH₂Si); 4.15 (s, 3H, CH₃O); 5.54 (s, 2H, NCH₂O); 6.96 (dd, 1H, *J*_{4,5} = 5.3 Hz, *J*_{4,3} = 3.6 Hz, H-4-Sthienyl); 7.16 (s, 1H, H-6); 7.24 (dd, 1H, *J*_{3,4} = 3.6 Hz, *J*_{3,5} = 1.3 Hz, H-3-Sthienyl); 7.31 (dd, 1H, *J*_{5,4} = 5.3 Hz, *J*_{5,3} = 1.3 Hz, H-5-Sthienyl); 8.46 (s, 1H, H-2). ¹³C NMR (125.7 MHz, CDCl₃): -1.48 (CH₃Si); 17.70 (OCH₂CH₂Si); 53.70 (CH₃O); 66.60 (OCH₂CH₂Si); 73.06 (NCH₂O); 105.45 (C-4a); 108.19 (C-5); 127.39 (CH-4-Sthienyl); 128.13 (CH-6); 129.26 (CH-5-Sthienyl); 132.73 (CH-3-Sthienyl); 135.02 (C-2-Sthienyl); 151.98 (CH-2); 152.87 (C-7a); 163.53 (C-4). IR (KBr): 3087, 3004, 2953, 2890, 1589, 1562, 1479, 1410, 1341, 1326, 1248, 1224, 1174, 1096, 1078, 866, 833. HRMS (ESI) calculated for C₁₇H₂₄O₂N₃S₂Si: 394.1074; found: 394.1074.


**4-Methoxy-5-(phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine
(6-methoxy-7-(phenylsulfanyl)-7-deazapurine) (1h)**



Protected deazapurine **5h** (774 mg, 2.0 mmol, 1 equiv) was dissolved in trifluoroacetic acid (2 mL) and the reaction mixture was stirred at rt overnight. The mixture was then diluted with NaHCO₃ (check pH=7!) and EtOAc (25 mL). The layers were separated and the aqueous layer was extracted two times with EtOAc (25 mL). The combined organic layers were dried over sodium sulfate (Na₂SO₄), and concentrated under the reduced pressure to give white solid. The solid was then diluted with aq. ammonia (25% [w/w], 15 mL) and stirred at rt overnight to form white precipitate. The precipitate was filtered to give product **1h** (460 mg, 90%) as a white powder.

M.p. 200 °C. ¹H NMR (600.1 MHz, DMSO-d₆): 3.86 (s, 3H, CH₃O); 7.07 (m, 2H, H-*o*-SPh); 7.10 (m, 1H, H-*p*-SPh); 7.23 (m, 2H, H-*m*-SPh); 7.71 (s, 1H, H-6); 8.41 (s, 1H, H-2); 12.54 (bs, 1H, NH). ¹³C NMR (150.9 MHz, DMSO-d₆): 53.57 (CH₃O); 99.54 (C-5); 105.71 (C-4a); 125.30 (CH-*p*-SPh); 126.20 (CH-*o*-SPh); 129.04 (CH-*m*-SPh); 131.31 (CH-6); 139.40 (C-*i*-SPh); 151.51 (CH-2); 153.58 (C-7a); 162.90 (C-4). IR (KBr): 3096, 2974, 2941, 2896, 2851, 2821, 1598, 1583, 1485, 1434, 1398, 1335, 1326, 1093, 878, 737. HRMS (ESI) calculated for C₁₃H₁₂ON₃S: 258.0696; found: 258.0696.

**4-Methoxy-5-[(thiophen-2-yl)sulfanyl]-7H-pyrrolo[2,3-d]pyrimidine
(6-methoxy-7-[(thiophen-2-yl)sulfanyl]-7-deazapurine) (2h)**




Compound **2h** was prepared as described for **1h** from 6-chloro-7-[(thiophen-2-yl)sulfanyl]-9-[[2-(trimethylsilyl)ethoxy]methyl]-7-deazapurine (**6h**) (787 mg, 2.0 mmol) to give deazapurine **2h** (462 mg, 88%) as a white powder.

M.p. 167 °C. ¹H NMR (401 MHz, DMSO-d₆): 4.03 (s, 3H, CH₃O); 6.98 (dd, 1H, *J*_{4,5} = 5.3 Hz, *J*_{4,3} = 3.6 Hz, H-4-Sthienyl); 7.20 (dd, 1H, *J*_{3,4} = 3.6 Hz, *J*_{3,5} = 1.3 Hz, H-3-Sthienyl); 7.50 (dd, 1H, *J*_{5,4} = 5.3 Hz, *J*_{5,3} = 1.3 Hz, H-5-Sthienyl); 7.60 (s, 1H, H-6); 8.39 (s, 1H, H-2); 12.41 (bs, 1H, NH). ¹³C NMR (100.8 MHz, DMSO-d₆): 53.56 (CH₃O); 104.10 (C-5); 104.91 (C-4a); 127.84 (CH-4-Sthienyl); 129.25 (CH-6); 129.46 (CH-5-Sthienyl); 131.46 (CH-3-Sthienyl); 136.58 (C-2-Sthienyl); 151.52 (CH-2); 153.07 (C-7a); 162.81 (C-4). IR (KBr): 3096, 2992, 2947, 2899, 2857, 2824, 1595, 1583, 1476, 1395, 1338, 1317, 1102, 713, 626. HRMS (ESI) calculated for C₁₁ H₁₀ O N₃ S₂: 264.0260; found: 264.0261.

General procedure for deprotection of 7-substituted nucleosides

A protected nucleoside **3b-3e** or **4b-4e** (1 equiv) was dissolved in methanol and 1 M solution of MeONa in MeOH (1.5 equiv) was added. Reaction mixture was stirred at rt overnight. Solvent was evaporated under reduced pressure and crude products were purified using RP-HPFC (0→100% of MeOH in H₂O).


4-(Thiophen-2-yl)-5-(phenylsulfanyl)-7-β-D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine (6-(thiophen-2-yl)-7-(phenylsulfanyl)-9-β-D-ribofuranosyl)-7-deazapurine) (**7b**)



Deprotection of **3b** (376 mg, 0.5 mmol) according to the general procedure afforded compound **7b** (164 mg, 75%) as yellow solid. Crystallization in MeOH/H₂O gave yellow foam.

M.p. 77 °C [α]_D -49.3 (0.19). ¹H NMR (401.0 MHz, DMSO-d₆): 3.59 (dd, 1H, J_{gem} = 12.0 Hz, $J_{5'a,4'}$ = 3.7 Hz, H-5'a); 3.69 (dd, 1H, J_{gem} = 12.0 Hz, $J_{5'b,4'}$ = 3.7 Hz, H-5'b); 3.97 (q, 1H, $J_{4',5'a} = J_{4',5'b} = J_{4',3'}$ = 3.7 Hz, H-4'); 4.15 (dd, 1H, $J_{3',2'}$ = 5.0 Hz, $J_{3',4'}$ = 3.6 Hz, H-3'); 4.46 (bt, 1H, $J_{2',1'} = J_{2',3'}$ = 5.4 Hz, H-2'); 5.06 – 5.64 (m, 3H, OH-2',3',5'); 6.33 (d, 1H, $J_{1',2'}$ = 5.8 Hz, H-1'); 6.93 (m, 2H, H-*o*-SPh); 7.04 (m, 1H, H-*p*-SPh); 7.08 (dd, 1H, $J_{4,5}$ = 5.1 Hz, $J_{4,3}$ = 3.8 Hz, H-4-thienyl); 7.16 (m, 2H, H-*m*-SPh); 7.71 (dd, 1H, $J_{5,4}$ = 5.1 Hz, $J_{5,3}$ = 1.1 Hz, H-5-thienyl); 8.35 (dd, 1H, $J_{3,4}$ = 3.8 Hz, $J_{3,5}$ = 1.1 Hz, H-3-thienyl); 8.41 (s, 1H, H-6); 8.84 (s, 1H, H-2). ¹³C NMR (100.8 MHz, DMSO-d₆): 61.37 (CH₂-5'); 70.51 (CH-3'); 74.60 (CH-2'); 85.56 (CH-4'); 87.26 (CH-1'); 100.37 (C-5); 114.66 (C-4a); 125.67 (CH-*p*-SPh); 125.83 (CH-*o*-SPh); 128.20 (CH-4-thienyl); 129.27 (CH-*m*-SPh); 131.08 (CH-5-thienyl); 132.28 (CH-3-thienyl); 136.12 (CH-6); 138.44 (C-*i*-SPh); 140.89 (C-2-thienyl); 151.22 (CH-2); 152.62 (C-4); 153.50 (C-7a). IR (KBr): 3117, 3052, 2923, 2869, 1559, 1482, 1437, 1404, 1195, 1105, 1081, 1048, 1021, 737.. HRMS (ESI) calculated for C₂₁H₂₀O₄N₃S₂: 442.0890; found: 442.0890.


4-(Furan-2-yl)-5-(phenylsulfanyl)-7-β-D-ribofuranosyl-pyrrolo[2,3-*d*]pyrimidine (6-(furan-2-yl)-7-(phenylsulfanyl)-9-β-D-ribofuranosyl)-7-deazapurine (7c)



Deprotection of **3c** (552 mg, 0.75 mmol) according to the general procedure afforded compound **7c** (248 mg, 78%) as yellow solid. Crystallization in MeOH/H₂O gave yellow solid.

M.p. 120 °C [α]_D -39.3 (0.19). ¹H NMR (500 MHz, DMSO-d₆): 3.59 (ddd, 1H, J_{gem} = 12.0 Hz, $J_{5'a,OH}$ = 5.5 Hz, $J_{5'a,4'}$ = 3.7 Hz, H-5'a); 3.68 (ddd, 1H, J_{gem} = 12.0 Hz, $J_{5'b,OH}$ = 5.3 Hz, $J_{5'b,4'}$ = 3.9 Hz, H-5'b); 3.97 (q, 1H, $J_{4',5'a}$ = $J_{4',5'b}$ = $J_{4',3'}$ = 3.7 Hz, H-4'); 4.15 (td, 1H, $J_{3',2'}$ = $J_{3',OH}$ = 5.0 Hz, $J_{3',4'}$ = 3.6 Hz, H-3'); 4.46 (td, 1H, $J_{2',1'}$ = $J_{2',OH}$ = 6.0 Hz, $J_{2',3'}$ = 5.0 Hz, H-2'); 5.13 (t, 1H, $J_{OH,5'a}$ = $J_{OH,5'b}$ = 5.4 Hz, OH-5'); 5.22 (d, 1H, $J_{OH,3'}$ = 5.0 Hz, OH-3'); 5.50 (d, 1H, $J_{OH,2'}$ = 6.1 Hz, OH-2'); 6.32 (d, 1H, $J_{1',2'}$ = 5.8 Hz, H-1'); 6.59 (dd, 1H, $J_{4,3}$ = 3.5 Hz, $J_{4,5}$ = 1.7 Hz, H-4-furyl); 7.01 (m, 2H, H-*o*-SPh); 7.05 (m, 1H, H-*p*-SPh); 7.18 (m, 2H, H-*m*-SPh); 7.42 (dd, 1H, $J_{3,4}$ = 3.5 Hz, $J_{3,5}$ = 0.9 Hz, H-3-furyl); 7.71 (dd, 1H, $J_{5,4}$ = 1.7 Hz, $J_{5,3}$ = 0.9 Hz, H-5-furyl); 8.38 (s, 1H, H-6); 8.87 (s, 1H, H-2). ¹³C NMR (125.7 MHz, DMSO-d₆): 61.39 (CH₂-5'); 70.54 (CH-3'); 74.54 (CH-2'); 85.55 (CH-4'); 87.09 (CH-1'); 100.90 (C-5); 112.43 (CH-4-furyl); 114.11 (C-4a); 115.27 (CH-3-furyl); 125.36 (CH-*p*-SPh); 125.76 (CH-*o*-SPh); 129.11 (CH-*m*-SPh); 135.98 (CH-6); 139.03 (C-*i*-SPh); 145.91 (CH-5-furyl); 148.09 (C-4); 150.63 (C-2-furyl); 151.41 (CH-2); 153.57 (C-7a). IR (KBr): 3294, 3135, 3117, 2947, 2920, 2902, 1580, 1556, 1482, 1440, 1326, 1204, 1108, 988, 734. HRMS (ESI) calculated for C₂₁H₂₀O₅N₃S: 426.1118; found: 426.1118. Anal. calculated for C₂₁H₁₉N₃O₅S·0.75H₂O: C, 57.46; H, 4.71; N, 9.57; S, 7.3; found: C, 57.77; H, 4.56; N, 9.21; S, 7.17.


4-Methyl-5-(phenylsulfanyl)-7-β-D-ribofuranosyl-pyrrolo[2,3-*d*]pyrimidine (6-methyl-7-(phenylsulfanyl)-9-β-D-ribofuranosyl)-7-deazapurine) (7d)



Deprotection of **3d** (274 mg, 0.4 mmol) according to the general procedure afforded compound **7d** (130 mg, 87%) as white solid. Crystallization in MeOH/H₂O gave white solid.

M.p. 182 °C [α]_D -54.5 (0.21). ¹H NMR (600.1 MHz, DMSO-d₆): 2.60 (s, 3H, CH₃-4); 3.58 (ddd, 1H, J_{gem} = 11.9 Hz, $J_{5'a,OH}$ = 5.5 Hz, $J_{5'a,4'}$ = 3.7 Hz, H-5'a); 3.67 (ddd, 1H, J_{gem} = 11.9 Hz, $J_{5'b,OH}$ = 5.2 Hz, $J_{5'b,4'}$ = 3.9 Hz, H-5'b); 3.95 (q, 1H, $J_{4',5'a}$ = $J_{4',5'b}$ = $J_{4',3'}$ = 3.7 Hz, H-4'); 4.14 (td, 1H, $J_{3',2'}$ = $J_{3',OH}$ = 4.9 Hz, $J_{3',4'}$ = 3.4 Hz, H-3'); 4.45 (td, 1H, $J_{2',1'}$ = $J_{2',OH}$ = 6.0 Hz, $J_{2',3'}$ = 5.0 Hz, H-2'); 5.11 (t, 1H, $J_{OH,5'a}$ = $J_{OH,5'b}$ = 5.4 Hz, OH-5'); 5.20 (d, 1H, $J_{OH,3'}$ = 4.9 Hz, OH-3'); 5.45 (d, 1H, $J_{OH,2'}$ = 6.1 Hz, OH-2'); 6.25 (d, 1H, $J_{1',2'}$ = 5.9 Hz, H-1'); 7.07 (m, 2H, H-*o*-SPh); 7.15 (m, 1H, H-*p*-SPh); 7.28 (m, 2H, H-*m*-SPh); 8.27 (s, 1H, H-6); 8.73 (s, 1H, H-2). ¹³C NMR (150.9 MHz, DMSO-d₆): 20.81 (CH₃-4); 61.46 (CH₂-5'); 70.56 (CH-3'); 74.44 (CH-2'); 85.53 (CH-4'); 87.10 (CH-1'); 100.54 (C-5); 117.80 (C-4a); 125.58 (CH-*o*-SPh); 125.69 (CH-*p*-SPh); 129.15 (CH-*m*-SPh); 134.14 (CH-6); 138.79 (C-*i*-SPh); 151.62 (C-7a); 151.79 (CH-2); 159.62 (C-4). IR (KBr): 3455, 3422, 3225, 3072, 2953, 2914, 2881, 2839, 1580, 1568, 1470, 1428, 1338, 1213, 1054, 1042, 740, 629. HRMS (ESI) calculated for C₁₈H₂₀O₄N₃S: 374.1169; found: 374.1170. Anal. calculated for C₁₈H₁₉N₃O₄S·0.3 H₂O: C, 57.07; H, 5.21; N, 11.09; S, 8.46; found: C, 57.12; H, 5.16; N, 10.92; S, 8.29.

4-(*N,N*-Dimethylamino)-5-(phenylsulfanyl)-7-β-D-ribofuranosyl-pyrrolo[2,3-*d*]pyrimidine
(6-(*N,N*-Dimethylamino)-7-(phenylsulfanyl)-9-β-D-ribofuranosyl)-7-deazapurine) (7e)




Deprotection of **3e** (535 mg, 0.75 mmol) according to the general procedure afforded compound **7e** (302 mg, 87%) as white solid. Crystallization in MeOH/H₂O gave white solid.

M.p. 112 °C [α]_D -44.4 (0.18). ¹H NMR (600.1 MHz, DMSO-d₆): 3.12 (s, 6H, (CH₃)₂N); 3.55 (ddd, 1H, J_{gem} = 12.0 Hz, $J_{5'a,OH}$ = 5.7 Hz, $J_{5'a,4'}$ = 3.7 Hz, H-5'a); 3.65 (ddd, 1H, J_{gem} = 12.0 Hz, $J_{5'b,OH}$ = 4.9 Hz, $J_{5'b,4'}$ = 3.7 Hz, H-5'b); 3.92 (q, 1H, $J_{4',5'a}$ = $J_{4',5'b}$ = $J_{4',3'}$ = 3.6 Hz, H-4');

4.10 (m, 1H, H-3'); 4.41 (m, 1H, H-2'); 5.13 – 5.17 (m, 2H, OH-3',5'); 5.39 (m, 1H, OH-2'); 6.18 (d, 1H, $J_{1',2'} = 5.9$ Hz, H-1'); 7.03 (m, 2H, H-*o*-SPh); 7.12 (m, 1H, H-*p*-SPh); 7.26 (m, 2H, H-*m*-SPh); 8.01 (s, 1H, H-6); 8.25 (s, 1H, H-2). ^{13}C NMR (150.9 MHz, DMSO- d_6): 41.26 ((CH $_3$) $_2$ N); 61.51 (CH $_2$ -5'); 70.53 (CH-3'); 74.30 (CH-2'); 85.32 (CH-4'); 87.33 (CH-1'); 99.61 (C-5); 104.95 (C-4a); 125.31 (CH-*o*-SPh); 125.45 (CH-*p*-SPh); 129.32 (CH-*m*-SPh); 131.82 (CH-6); 139.39 (C-*i*-SPh); 150.78 (CH-2); 152.83 (C-7a); 159.39 (C-4). IR (KBr): 3515, 3407, 3192, 3114, 3052, 2941, 2902, 2863, 1571, 1547, 1491, 1416, 1296, 1096, 1057, 1030, 740. HRMS (ESI) calculated for C $_{19}$ H $_{23}$ O $_4$ N $_4$ S: 403.1435; found: 403.1436. Anal. calculated for C $_{19}$ H $_{22}$ N $_4$ O $_4$ S·1.15H $_2$ O: C, 53.93; H, 5.79; N, 13.24; S, 7.58; found: C, 54.14; H, 5.72; N, 13.03; S, 7.48.

4-Methoxy-5-(phenylsulfanyl)-7- β -D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine (6-methoxy-7-(phenylsulfanyl)-9- β -D-ribofuranosyl)-7-deazapurine) (7h)




Deprotection and methoxylation of **3a** (706 mg, 1 mmol) according to the general procedure (4 equiv of NaOMe were used) afforded compound **7h** (290 mg, 75%) as white solid. Crystallization in MeOH/H $_2$ O gave white solid.

M.p. 162 °C [α] $_D$ –55.1 (0.18). ^1H NMR (600.1 MHz, DMSO- d_6): 3.56 (ddd, 1H, $J_{gem} = 12.0$ Hz, $J_{5'a,OH} = 5.7$ Hz, $J_{5'a,4'} = 3.8$ Hz, H-5'a); 3.65 (ddd, 1H, $J_{gem} = 12.0$ Hz, $J_{5'b,OH} = 5.2$ Hz, $J_{5'b,4'} = 3.9$ Hz, H-5'b); 3.87 (s, 3H, CH $_3$ O-4); 3.93 (q, 1H, $J_{4',5'a} = J_{4',5'b} = J_{4',3'} = 3.7$ Hz, H-4'); 4.11 (td, 1H, $J_{3',2'} = J_{3',OH} = 4.9$ Hz, $J_{3',4'} = 3.4$ Hz, H-3'); 4.42 (m, 1H, H-2'); 5.10 (t, 1H, $J_{OH,5'a} = J_{OH,5'b} = 5.4$ Hz, OH-5'); 5.18 (d, 1H, $J_{OH,3'} = 4.8$ Hz, OH-3'); 5.42 (d, 1H, $J_{OH,2'} = 6.0$ Hz, OH-2'); 6.18 (d, 1H, $J_{1',2'} = 6.0$ Hz, H-1'); 7.11 (m, 2H, H-*o*-SPh); 7.13 (m, 1H, H-*p*-SPh); 7.26 (m, 2H, H-*m*-SPh); 8.04 (s, 1H, H-6); 8.48 (s, 1H, H-2). ^{13}C NMR (150.9 MHz, DMSO- d_6): 53.83 (CH $_3$ O-4); 61.52 (CH $_2$ -5'); 70.59 (CH-3'); 74.44 (CH-2'); 85.53 (CH-4');

87.40 (CH-1'); 101.02 (C-5); 106.28 (C-4a); 125.61 (CH-*p*-SPh); 126.51 (CH-*o*-SPh); 129.14 (CH-*m*-SPh); 131.09 (CH-6); 138.61 (C-*i*-SPh); 151.73 (CH-2); 152.96 (C-7a); 162.97 (C-4). IR (KBr): 3225, 3150, 3058, 3016, 3001, 2941, 2908, 2869, 2848, 1589, 1556, 1479, 1449, 1419, 1344, 1299, 1072, 1051, 737. HRMS (ESI) calculated for C₁₈H₂₀O₅N₃S: 390.1118; found: 390.1119.

**4-(Thiophen-2-yl)-5-[(thiophen-2-yl)sulfanyl]-7-β-D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine
(6-(thiophen-2-yl)-7-[(thiophen-2-yl)sulfanyl]-9-β-D-ribofuranosyl)-7-deazapurine) (8b)**




Deprotection of **4b** (462 mg, 0.65 mmol) according to the general procedure afforded compound **8b** (171 mg, 59%) as yellowish solid.

M.p. 165 °C [α]_D −31.2 (0.19). ¹H NMR (401.0 MHz, DMSO-*d*₆): 3.60 (dd, 1H, *J*_{gem} = 12.0 Hz, *J*_{5'a,4'} = 3.8 Hz, H-5'a); 3.70 (dd, 1H, *J*_{gem} = 12.0 Hz, *J*_{5'b,4'} = 3.8 Hz, H-5'b); 3.97 (q, 1H, *J*_{4',5'a} = *J*_{4',5'b} = *J*_{4',3'} = 3.7 Hz, H-4'); 4.15 (dd, 1H, *J*_{3',2'} = 5.0 Hz, *J*_{3',4'} = 3.6 Hz, H-3'); 4.43 (bt, 1H, *J*_{2',1'} = *J*_{2',3'} = 5.4 Hz, H-2'); 4.96 – 5.66 (m, 3H, OH-2', 3', 5'); 6.28 (d, 1H, *J*_{1',2'} = 5.7 Hz, H-1'); 6.79 (dd, 1H, *J*_{3,4} = 3.6 Hz, *J*_{3,5} = 1.3 Hz, H-3-Sthienyl); 6.85 (dd, 1H, *J*_{4,5} = 5.3 Hz, *J*_{4,3} = 3.6 Hz, H-4-Sthienyl); 7.30 (dd, 1H, *J*_{4,5} = 5.1 Hz, *J*_{4,3} = 3.7 Hz, H-4-thienyl); 7.41 (dd, 1H, *J*_{5,4} = 5.3 Hz, *J*_{5,3} = 1.3 Hz, H-5-Sthienyl); 7.86 (dd, 1H, *J*_{5,4} = 5.1 Hz, *J*_{5,3} = 1.1 Hz, H-5-thienyl); 8.38 (s, 1H, H-6); 8.40 (dd, 1H, *J*_{3,4} = 3.7 Hz, *J*_{3,5} = 1.1 Hz, H-3-thienyl); 8.82 (s, 1H, H-2). ¹³C NMR (100.8 MHz, DMSO-*d*₆): 61.41 (CH₂-5'); 70.51 (CH-3'); 74.56 (CH-2'); 85.57 (CH-4'); 87.29 (CH-1'); 104.92 (C-5); 113.99 (C-4a); 127.83 (CH-4-Sthienyl); 128.31 (CH-4-thienyl); 129.54 (CH-5-Sthienyl); 130.56 (CH-3-Sthienyl); 131.15 (CH-5-thienyl); 132.91 (CH-3-thienyl); 134.53 (CH-6); 136.03 (C-2-Sthienyl); 140.81 (C-2-thienyl); 151.21

(CH-2); 152.52 (C-4); 152.94 (C-7a). IR (KBr): 3291, 3111, 2932, 2869, 1556, 1443, 1401, 1192, 1099, 1075, 1045, 803, 716, 629. HRMS (ESI) calculated for C₁₉H₁₈O₄N₃S₃: 448.0454; found: 448.0453.

4-(Furan-2-yl)-5-[(thiophen-2-yl)sulfanyl]-7-β-D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine

(6-(furan-2-yl)-7-[(thiophen-2-yl)sulfanyl]-9-β-D-ribofuranosyl)-7-deazapurine) (8c)




Deprotection of **4c** (260 mg, 0.35 mmol) according to the general procedure afforded compound **8c** (85 mg, 57%) as yellow solid.

M.p. 172 °C [α]_D -41.7 (0.21). ¹H NMR (401.0 MHz, DMSO-d₆): 3.56 (dd, 1H, J_{gem} = 11.9 Hz, $J_{5'a,4'}$ = 3.8 Hz, H-5'a); 3.66 (dd, 1H, J_{gem} = 11.9 Hz, $J_{5'b,4'}$ = 3.8 Hz, H-5'b); 3.95 (q, 1H, $J_{4',5'a} = J_{4',5'b} = J_{4',3'}$ = 3.7 Hz, H-4'); 4.11 (dd, 1H, $J_{3',2'}$ = 5.0 Hz, $J_{3',4'}$ = 3.6 Hz, H-3'); 4.39 (bt, 1H, $J_{2',1'} = J_{2',3'}$ = 5.4 Hz, H-2'); 4.96 – 5.67 (m, 3H, OH-2',3',5'); 6.25 (d, 1H, $J_{1',2'}$ = 5.8 Hz, H-1'); 6.78 (dd, 1H, $J_{4,3}$ = 3.5 Hz, $J_{4,5}$ = 1.8 Hz, H-4-furyl); 6.93 (dd, 1H, $J_{4,5}$ = 5.3 Hz, $J_{4,3}$ = 3.6 Hz, H-4-Sthienyl); 7.02 (dd, 1H, $J_{3,4}$ = 3.6 Hz, $J_{3,5}$ = 1.3 Hz, H-3-Sthienyl); 7.48 (dd, 1H, $J_{5,4}$ = 5.3 Hz, $J_{5,3}$ = 1.3 Hz, H-5-Sthienyl); 7.50 (dd, 1H, $J_{3,4}$ = 3.5 Hz, $J_{3,5}$ = 0.9 Hz, H-3-furyl); 8.05 (dd, 1H, $J_{5,4}$ = 1.8 Hz, $J_{5,3}$ = 0.9 Hz, H-5-furyl); 8.17 (s, 1H, H-6); 8.83 (s, 1H, H-2). ¹³C NMR (100.8 MHz, DMSO-d₆): 61.44 (CH₂-5'); 70.55 (CH-3'); 74.51 (CH-2'); 85.52 (CH-4'); 87.16 (CH-1'); 106.19 (C-5); 112.74 (CH-4-furyl); 113.10 (C-4a); 115.42 (CH-3-furyl); 127.95 (CH-4-Sthienyl); 129.71 (CH-5-Sthienyl); 131.25 (CH-3-Sthienyl); 133.07 (CH-6); 135.74 (C-2-Sthienyl); 146.18 (CH-5-furyl); 147.87 (C-4); 150.87 (C-2-furyl); 151.33 (CH-2); 152.96 (C-7a). IR (KBr): 3252, 3162, 3138, 2944, 2914, 2872, 1586,

1562, 1532, 1461, 1338, 1198, 1096, 1054, 1024, 979, 812, 752, 704. HRMS (ESI) calculated for $C_{19}H_{17}O_5N_3NaS_2$: 454.0502; found: 454.0502.

4-Methyl-5-[(thiophen-2-yl)sulfanyl]-7- β -D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine (6-methyl-7-[(thiophen-2-yl)sulfanyl]-9- β -D-ribofuranosyl)-7-deazapurine) (8d**)**




Deprotection of **4d** (415 mg, 0.6 mmol) according to the general procedure afforded compound **8d** (146 mg, 64%) as white solid.

M.p. 140 °C [α]_D −53.0 (0.22). 1H NMR (401.0 MHz, DMSO- d_6): 2.83 (s, 3H, CH₃); 3.57 (dd, 1H, $J_{gem} = 11.9$ Hz, $J_{5'a,4'} = 3.8$ Hz, H-5'a); 3.68 (dd, 1H, $J_{gem} = 11.9$ Hz, $J_{5'b,4'} = 3.9$ Hz, H-5'b); 3.94 (q, 1H, $J_{4',5'a} = J_{4',5'b} = J_{4',3'} = 3.7$ Hz, H-4'); 4.12 (dd, 1H, $J_{3',2'} = 5.1$ Hz, $J_{3',4'} = 3.5$ Hz, H-3'); 4.41 (dd, 1H, $J_{2',1'} = 5.9$ Hz, $J_{2',3'} = 5.1$ Hz, H-2'); 5.00 – 5.55 (m, 3H, OH-2', 3', 5'); 6.20 (d, 1H, $J_{1',2'} = 5.9$ Hz, H-1'); 7.00 (dd, 1H, $J_{4,5} = 5.3$ Hz, $J_{4,3} = 3.6$ Hz, H-4-Sthienyl); 7.16 (dd, 1H, $J_{3,4} = 3.6$ Hz, $J_{3,5} = 1.3$ Hz, H-3-Sthienyl); 7.51 (dd, 1H, $J_{5,4} = 5.3$ Hz, $J_{5,3} = 1.3$ Hz, H-5-Sthienyl); 8.27 (s, 1H, H-6); 8.71 (s, 1H, H-2). ^{13}C NMR (100.8 MHz, DMSO- d_6): 21.60 (CH₃); 61.50 (CH₂-5'); 70.55 (CH-3'); 74.45 (CH-2'); 85.54 (CH-4'); 87.18 (CH-1'); 104.53 (C-5); 117.14 (C-4a); 128.20 (CH-4-Sthienyl); 128.85 (CH-5-Sthienyl); 129.50 (CH-3-Sthienyl); 133.11 (CH-6); 137.12 (C-2-Sthienyl); 151.10 (C-7a); 151.76 (CH-2); 159.90 (C-4). IR (KBr): 3425, 3282, 3108, 2950, 2932, 2881, 2842, 1583, 1562, 1416, 1407, 1338, 1219, 1207, 1117, 1096, 1057, 1039, 976, 848, 710, 695, 626. HRMS (ESI) calculated for $C_{16}H_{17}O_4N_3NaS_2$: 402.0553; found: 402.0553.

4-(*N,N*-Dimethylamino)-5-[(thiophen-2-yl)sulfanyl]-7- β -D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine


(6-(*N,N*-Dimethylamino)-7-[(thiophen-2-yl)sulfanyl]-9- β -D-ribofuranosyl)-7-deazapurine) (8e)



Deprotection of **4e** (540 mg, 0.75 mmol) according to the general procedure afforded compound **8e** (197 mg, 65%) as white solid.

M.p. 199 °C [α]_D -41.8 (0.19). ¹H NMR (401.0 MHz, DMSO-*d*₆): 3.24 (s, 6H, (CH₃)₂N); 3.55 (dd, 1H, *J*_{gem} = 11.9 Hz, *J*_{5'a,4'} = 3.7 Hz, H-5'a); 3.65 (dd, 1H, *J*_{gem} = 11.9 Hz, *J*_{5'b,4'} = 3.7 Hz, H-5'b); 3.91 (q, 1H, *J*_{4',5'a} = *J*_{4',5'b} = *J*_{4',3'} = 3.7 Hz, H-4'); 4.09 (dd, 1H, *J*_{3',2'} = 5.1 Hz, *J*_{3',4'} = 3.6 Hz, H-3'); 4.36 (dd, 1H, *J*_{2',1'} = 5.8 Hz, *J*_{2',3'} = 5.1 Hz, H-2'); 5.00 – 5.51 (m, 3H, OH-2', 3', 5'); 6.11 (d, 1H, *J*_{1',2'} = 5.8 Hz, H-1'); 6.97 (dd, 1H, *J*_{4,5} = 5.3 Hz, *J*_{4,3} = 3.6 Hz, H-4-Sthienyl); 7.10 (dd, 1H, *J*_{3,4} = 3.6 Hz, *J*_{3,5} = 1.3 Hz, H-3-Sthienyl); 7.48 (dd, 1H, *J*_{5,4} = 5.3 Hz, *J*_{5,3} = 1.3 Hz, H-5-Sthienyl); 8.23 (s, 1H, H-6); 8.30 (s, 1H, H-2). ¹³C NMR (100.8 MHz, DMSO-*d*₆): 41.54 ((CH₃)₂N); 61.57 (CH₂-5'); 70.54 (CH-3'); 74.32 (CH-2'); 85.33 (CH-4'); 87.44 (CH-1'); 104.37 and 104.47 (C-4a,5); 128.05 (CH-4-Sthienyl); 128.93 (CH-5-Sthienyl); 129.82 (CH-3-Sthienyl); 130.12 (CH-6); 137.39 (C-2-Sthienyl); 150.76 (CH-2); 152.35 (C-7a); 159.53 (C-4). IR (KBr): 3494, 3282, 3222, 3117, 2941, 2887, 1577, 1538, 1497, 1437, 1419, 1404, 1299, 1219, 1135, 1030, 698. HRMS (ESI) calculated for C₁₇H₂₁O₄N₄S₂: 409.0999; found: 409.1002.

**4-Methoxy-5-[(thiophen-2-yl)sulfanyl]-7-β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine
(6-methoxy-7-[(thiophen-2-yl)sulfanyl]-9-β-D-ribofuranosyl)-7-deazapurine) (8h)**





Deprotection and methoxylation of **4a** (712 mg, 1 mmol) according to the general procedure (4 equiv of NaOMe were used) afforded compound **8h** (305 mg, 77%) as white solid.



M.p. 194 °C [α]_D -51.1 (0.17). ¹H NMR (401.0 MHz, DMSO-d₆): 3.55 (dd, 1H, J_{gem} = 11.9 Hz, $J_{5'a,4'}$ = 3.8 Hz, H-5'a); 3.64 (dd, 1H, J_{gem} = 11.9 Hz, $J_{5'b,4'}$ = 3.8 Hz, H-5'b); 3.91 (q, 1H, $J_{4',5'a} = J_{4',5'b} = J_{4',3'}$ = 3.6 Hz, H-4'); 4.06 (s, 3H, CH₃O); 4.09 (dd, 1H, $J_{3',2'}$ = 5.1 Hz, $J_{3',4'}$ = 3.4 Hz, H-3'); 4.37 (dd, 1H, $J_{2',1'}$ = 6.1 Hz, $J_{2',3'}$ = 5.1 Hz, H-2'); 4.98 – 5.52 (m, 3H, OH-2',3',5'); 6.12 (d, 1H, $J_{1',2'}$ = 6.1 Hz, H-1'); 7.00 (dd, 1H, $J_{4,5}$ = 5.3 Hz, $J_{4,3}$ = 3.6 Hz, H-4-Sthienyl); 7.24 (dd, 1H, $J_{3,4}$ = 3.6 Hz, $J_{3,5}$ = 1.3 Hz, H-3-Sthienyl); 7.55 (dd, 1H, $J_{5,4}$ = 5.3 Hz, $J_{5,3}$ = 1.3 Hz, H-5-Sthienyl); 7.93 (s, 1H, H-6); 8.45 (s, 1H, H-2). ¹³C NMR (100.8 MHz, DMSO-d₆): 53.83 (CH₃O); 61.55 (CH₂-5'); 70.60 (CH-3'); 74.36 (CH-2'); 85.54 (CH-4'); 87.39 (CH-1'); 105.39 and 105.53 (C-4a,5); 127.93 (CH-4-Sthienyl); 129.13 (CH-6); 129.96 (CH-5-Sthienyl); 132.18 (CH-3-Sthienyl); 135.41 (C-2-Sthienyl); 151.73 (CH-2); 152.47 (C-7a); 162.89 (C-4). IR (KBr): 3512, 3285, 3025, 2992, 2935, 2920, 2869, 1589, 1556, 1482, 1443, 1407, 1338, 1326, 1302, 1138, 1081, 1036, 704. HRMS (ESI) calculated for C₁₆H₁₈O₅N₃S₂: 396.0682; found: 396.0682.


References:

1. Klečka, M.; Pohl, R.; Klepetářová, B; Hocek, M. *Org. Biomol. Chem.* **2013**, *11*, 5189-5193.

2. Copies of NMR spectra








Klecka_IK689-I
1H-NMR in CDCl₃
16-06-2014 LS

```



NAME      Klecka_IK689-I
EXPNO     1
PROCNO    1
Date_     20140616
Time      10.43
INSTRUM   spect
PROBHD    5 mm CPTXI 1H-
PULPROG   zgpg30
TD         70026
SOLVENT   CDCl3
NS         32
DS         0
SWH        7002.801 Hz
FIDRES     0.1000003 Hz
AQ         4.9999065 sec
RG         19.56
DW         71.400 usec
DE         18.00 usec
TE         300.0 K
D1         1.00000000 sec
TD0        1
===== CHANNEL f1 =====
SFO1      499.9625999 MHz
NUC1       1H
P1         10.00 usec
SI         131072
SF         499.9601111 MHz
WDW        no
SSB        0
LB          0.00 Hz
GB          0
PC          1.00
  
```






Klecka_IK689-I
APT-13C-NMR in CDCl₃
16-06-2014 LS


```


NAME      Klecka_IK689-I
EXPNO     2
PROCNO    1
Date_     20140616
Time      10.50
INSTRUM   spect
PROBHD    5 mm CPTXI 1H-
PULPROG   zgpg30
TD         69500
SOLVENT   CDCl3
NS         1000
DS         0
SWH        29791.004 Hz
FIDRES     0.000032 Hz
AQ         0.0000000 sec
RG         199.71
DW         18.00 usec
DE         18.00 usec
TE         300.0 K
CNST2     145.0000000
CNST11    1.0000000
D1         2.00000000 sec
TD0        0.00000000 sec
===== CHANNEL f1 =====
SFO1      125.761574 MHz
NUC1       13C
P1         13.00 usec
SI         26.85 usec
SF         125.760758 MHz
WDW        EM
SSB        0
LB          0.50 Hz
GB          0
PC          1.40
  
```












Klecka_IK-674-I
1H in DMSO
22-01-14 LS

NAME Klecka_IK-674-I
EXPNO 1
PROCNO 1
Date_ 20140122
Time 10.24
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zg30
TD 49998
SOLVENT DMSO
NS 32
DS 0
SWH 6996.269 Hz
FIDRES 0.135931 Hz
AQ 3.5732405 sec
RG 724
DW 71.487 usec
DE 20.00 usec
TE 300.0 K
D1 0.00000000 sec
TD0



===== CHANNEL f1 =====
NUC1 1H
P1 11.68 usec
PL1 -2.00 dB
PL1W 31.84857368 W
SFO1 499.8429990 MHz
SI 131072
SF 499.8420038 MHz
WDW no
SSB 0
LB 0.00 Hz
GB 0
PC 40.00







Klecka_IK-674-I
APT in DMSO
22-01-14 LS



NAME Klecka_IK-674-I
EXPNO 2
PROCNO 1
Date_ 20140122
Time 10.45
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG mod
TD 65536
SOLVENT DMSO
NS 962
DS 4
SWH 29781.004 Hz
FIDRES 0.454131 Hz
AQ 11.1010548 sec
RG 2050
DW 10.800 usec
DE 6.00 usec
TE 300.0 K
CNST2 145.0000000
CNST11 1.0000000
D1 2.00000000 sec
D20 0.0069605 sec
TD0


===== CHANNEL f1 =====
NUC1 13C
P1 8.00 usec
PL1 10.00 usec
PL1 -0.30 dB
PL1W 104.90646029 W
SFO1 125.0074305 MHz
===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 80.00 usec
PL2 -2.00 dB
PL2 14.71 dB
PL2W 31.84857368 W
SFO2 499.8419994 MHz
SI 131072
SF 125.0842045 MHz
WDW BM
SSB 0
LB 2.00 Hz
GB 0
PC 0.50















Klecka_IK696-I
1H NMR in DMSO
10-04-14 LS

NAME Klecka_IK696-I
EXPNO 1
PROCNO 1
Date_ 20140410
Time 11.13
INSTRUM spect
PROBHD 5 mm BBO BB-1H
PULPROG zg30
TD 65102
SOLVENT DMSO
NS 32
DS 0
SWH 6510.417 Hz
FIDRES 0.100003 Hz
AQ 4.9999604 sec
RG 322.5
DW 76.800 usec
DE 6.00 usec
TE 298.1 K
D1 1.0000000 sec
TD0 1


===== CHANNEL f1 =====
NUC1 1H
P1 11.70 usec
PL1 -4.00 dB
PL1W 21.45254898 W
SFO1 499.9531997 MHz
SI 131072
SF 499.9499991 MHz
WDW no
SSB 0
LB 0.00 Hz
GB 0
PC 1.00



Klecka_IK696-I
APT in DMSO
10-04-14 LS

NAME Klecka_IK696-I
EXPNO 2
PROCNO 1
Date_ 20140410
Time 11.44
INSTRUM spect
PROBHD 5 mm BBO BB-1H
PULPROG jmod
TD 65536
SOLVENT DMSO
NS 551
DS 4
SWH 30030.029 Hz
FIDRES 0.458222 Hz
AQ 1.0912410 sec
RG 32768
DW 18.620 usec
DE 6.50 usec
TE 298.1 K
CNST2 145.0000000
CNST11 1.0000000
D1 2.0000000 sec
D10 0.0089655 sec
TD0 1


===== CHANNEL f1 =====
NUC1 13C
P1 6.30 usec
PL1 -2.00 dB
PL1W 107.48803739 W
SFO1 125.7250687 MHz
===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 80.00 usec
PL2 -3.70 dB
PL12 11.50 dB
PL12W 20.0208630 W
SFO2 499.9519998 MHz
SI 131072
SF 125.7125943 MHz
WDW EM
SSB 0
LB 2.00 Hz
GB 0
PC 1.00



Klecka_K684-I
1H NMR in CDCl3
25-02-14 LS

NAME Klecka_K684-I
EXPNO 1
PROCNO 1
Date_ 20140225
Time 11:19
INSTRUM spect
PROBHD 5 mm TBO BB-1H
PULPROG zg30
TD 69960
SOLVENT CDCl3
NS 32
DS 0
SWH 6996.269 Hz
FIDRES 0.100004 Hz
AQ 4.9986579 sec
RG 1030
DW 71.467 usec
DE 20.00 usec
TE 298.1 K
D1 0.00000000 sec
TD0 1



===== CHANNEL f1 =====
NUC1 1H
P1 11.68 usec
PL1 -2.00 dB
PL1W 31.84857368 W
SFO1 499.8429990 MHz
SI 131072
SF 499.8400118 MHz
WDW no
SSB 0
LB 0.00 Hz
GB 0
PC 1.00




Klecka_K684-I
APT in CDCl3
25-02-14 LS

NAME Klecka_K684-I
EXPNO 2
PROCNO 1
Date_ 20140225
Time 12:07
INSTRUM spect
PROBHD 5 mm TBO BB-1H
PULPROG jmod
TD 65536
SOLVENT CDCl3
NS 10240
DS 4
SWH 29781.904 Hz
FIDRES 0.454131 Hz
AQ 1.1010548 sec
RG 2050
DW 18.500 usec
DE 20.00 usec
TE 298.1 K
CNST2 160.0000000
CNST11 1.0000000
D1 2.00000000 sec
D20 0.00025000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 13C
P1 8.00 usec
P2 18.00 usec
PL1 -0.30 dB
PL1W 104.9886563 W
SFO1 125.6074365 MHz
===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 80.00 usec
PL2 -2.00 dB
PL2 14.71 dB
PL2W 31.84857368 W
PL12W 0.97634638 W
SFO2 499.8419994 MHz
SI 131072
SF 125.6848708 MHz
WDW EM
SSB 0
LB 0.50 Hz
GB 0
PC 1.30






Klecka_IK-686-I
1H in CDCl₃
07-03-14 LS

NAME Klecka_IK-686-I
EXPNO 1
PROCNO 1
Date_ 20140307
Time 9.16
INSTRUM spect
PROBHD 5 mm TBO BB-1H
PULPROG zg30
TD 49998
SOLVENT CDCl₃
NS 32
DS 0
SWH 5000.000 Hz
FIDRES 0.100004 Hz
AQ 4.9998498 sec
RG 362
DW 100.000 usec
DE 20.00 usec
TE 300.0 K
D1 0.00000000 sec
TD0 1


===== CHANNEL f1 =====
NUC1 ¹H
P1 11.68 usec
PL1 -2.00 dB
PL1W 31.84657368 W
SFO1 499.8422493 MHz
SI 131072
SF 499.8400118 MHz
WDW no
SSB 0
LB 0.00 Hz
GB 0
PC 40.00



Klecka_IK-686-I
APT in CDCl₃
07-03-14 LS

NAME Klecka_IK-686-I
EXPNO 2
PROCNO 1
Date_ 20140307
Time 10.23
INSTRUM spect
PROBHD 5 mm TBO BB-1H
PULPROG mod
TD 65536
SOLVENT CDCl₃
NS 1270
DS 0
SWH 20781.804 Hz
FIDRES 0.454131 Hz
AQ 1.1010548 sec
RG 2050
DW 16.800 usec
DE 8.00 usec
TE 300.0 K
CNST2 145.000000
CNST11 1.0000000
D1 2.00000000 sec
D20 0.00000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 ¹³C
P1 8.00 usec
P2 16.00 usec
PL1 -2.30 dB
PL1W 104.6868028 W
SFO1 125.6674385 MHz
===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 ¹H
PCPD2 60.00 usec
PL2 -2.00 dB
PL12 14.71 dB
PL2W 31.84657368 W
PL12W 0.67634438 W
SFO2 499.8419504 MHz
SI 131072
SF 125.6868559 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 0.50




Klecka_IK702-I
1H NMR in CDCl₃
01-07-2014 LS

```

NAME      Klecka_IK702-I
EXPNO     1
PROCNO    1
Date_     20140701
Time      16.16
INSTRUM    spect
PROBHD     5 mm PABBO BB-
PULPROG    zgpg
TD         65536
SOLVENT    CDCl3
NS         32
DS         0
SWH        5499.894 Hz
FIDRES     0.100002 Hz
AQ         4.9999285 sec
RG         144.42
DW         90.933 usec
DE         6.50 usec
TE         298.0 K
D1         1.00000000 sec
TD0        1

===== CHANNEL f1 =====
SFO1      499.9824599 MHz
NUC1       1H
P1         9.00 usec
SI         131072
SF         499.9800121 MHz
WDW        nc
SSB        0
LB         0.00 Hz
GB         0
PC         1.00

```





Klecka_IK702-I
APT-13C-NMR in CDCl₃
01-07-2014 LS



```



NAME      Klecka_IK702-I
EXPNO     2
PROCNO    2
Date_     20140701
Time      16.43
INSTRUM    spect
PROBHD     5 mm PABBO BB-
PULPROG    zgpg
TD         65536
SOLVENT    CDCl3
NS         63
DS         0
SWH        20791.004 Hz
FIDRES     0.500032 Hz
AQ         0.6666667 sec
RG         199.71
DW         19.900 usec
DE         6.50 usec
TE         298.0 K
CNST2     160.0000000
CNST11     1.0000000
D1         2.00000000 sec
TD0        0.00000000 sec


===== CHANNEL f1 =====
SFO1      125.732716 MHz
NUC1      13C
P1         7.60 usec
P2         15.20 usec
SI         131072
SF         125.7209729 MHz
WDW        EM
SSB        0
LB         1.00 Hz
GB         0
PC         1.40

```










KLECKA IK-664-I
1H NMR in CDCl3
13-12-13 RA

NAME KLECKA IK-664-I-new
EXPNO 1
PROCNO 1
Date_ 20131213
Time 8.19
INSTRUM spect
PROBHD 5 mm CPBBO BB-
PULPROG zg30
TD 51226
SOLVENT CDCl3
NS 32
DS 0
SWH 5122.951 Hz
FIDRES 0.100007 Hz
AQ 4.9998050 sec
RG 10.1
DW 97.600 usec
DE 6.00 usec
TE 298.0 K
D1 1.00000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 1H
P1 12.00 usec
PL1 -2.20 dB
PL1W 14.17355919 W
SFO1 499.9524608 MHz
SI 131072
SF 499.9500078 MHz
WDW no
SSB 0
LB 0.00 Hz
GB 0
PC 3.00






KLECKA IK-664-I
APT in CDCl3
13-12-13 RA

NAME KLECKA IK-664-I-new
EXPNO 2
PROCNO 1
Date_ 20131213
Time 8.28
INSTRUM spect
PROBHD 5 mm CPBBO BB-
PULPROG mod
TD 65538
SOLVENT CDCl3
NS 2001
DS 4
SWH 30030.029 Hz
FIDRES 0.4582222 Hz
AQ 1.0612410 sec
RG 8162
DW 18.650 usec
DE 6.60 usec
TE 298.0 K
CNST2 160.0000000
CNST11 1.0000000
D1 2.00000000 sec
D00 0.00000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 13C
P1 10.00 usec
P2 20.00 usec
PL1 3.55 dB
PL1W 29.64771957 W
SFO1 125.7250687 MHz

===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 80.00 usec
PL2 -2.80 dB
PL2 18.89 dB
PL2W 15.54036840 W
PL2W 0.22053670 W
SFO2 499.9519668 MHz
SI 131072
SF 125.7125318 MHz
WDW EM
SSB 1.00 Hz
LB 0
GB 0
PC 1.00






Klecka_IK-676-I
1H in CDCl₃
04-03-14 LS

NAME Klecka_IK-676-I
EXPNO 1
PROCNO 1
Date_ 20140304
Time 11.03
INSTRUM spect
PROBHD 5 mm TBO BB-1H
PULPROG zg30
TD 49996
SOLVENT CDCl₃
NS 32
DS 0
SWH 5000.000 Hz
FIDRES 0.100004 Hz
AQ 4.9998458 sec
RG 362
DW 100.000 usec
DE 20.00 usec
TE 300.0 K
D1 0.00000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 1H
P1 11.68 usec
PL1 -2.00 dB
PL1W 31.64857368 W
SFO1 499.8424492 MHz
SI 131072
SF 499.8400119 MHz
WDW no
SSB 0
LB 0.00 Hz
GB 0
PC 40.00




Klecka_IK-676-I
APT in CDCl₃
04-03-14 LS

NAME Klecka_IK-676-I
EXPNO 2
PROCNO 1
Date_ 20140304
Time 11.23
INSTRUM spect
PROBHD 5 mm TBO BB-1H
PULPROG mod
TD 65536
SOLVENT CDCl₃
NS 2302
DS 4
SWH 20761.904 Hz
FIDRES 0.454131 Hz
AQ 1.1010549 sec
RG 2050
DW 16.600 usec
DE 6.00 usec
TE 300.0 K
CNST2 145.000000
CNST11 1.0000000
D1 2.00000000 sec
D30 0.00069055 sec
TD0 1

===== CHANNEL f1 =====
NUC1 13C
P1 9.00 usec
P2 18.00 usec
PL1 -2.00 dB
PL1W 104.6565026 W
SFO1 125.6674365 MHz

===== CHANNEL f2 =====
NUC2 1H
PCPD2 80.00 usec
PL2 -2.00 dB
PL12 14.71 dB
PL2W 31.94857368 W
SFO2 0.67534438 W
SFO2 499.8419994 MHz
SI 131072
SF 125.6846011 MHz
WDW EM
SSB 0
LB 2.00 Hz
GB 0
PC 0.50




Klecka_IK-705-I
1H in CDCl₃
07-07-14 LS

```

NAME      Klecka_IK-705-I
EXPNO     1
PROCNO    1
Date_     20140707
Time      17.57
INSTRUM    spect
PROBHD     5 mm PABO BB-
PULPROG    zgpg30
TD         49598
SOLVENT    CDCl3
NS         82
DS         5000.000 Hz
FIDRES     0.100004 Hz
AQ         4.9998498 sec
RG         575
DM         100.000 usec
DE         20.00 usec
TE         298.0 K
D1         0.0000000 sec
TDO        1
===== CHANNEL f1 =====
NUC1       13C
P1         14.00 usec
PL1        -1.44 dB
PL1W       27.8861310 W
SFO1       499.5463987 MHz
SI         131072
SF         499.9400151 MHz
SSB        0
GB         0.00 Hz
PC         20.00

```




Klecka_IK-705-I
APT in CDCl₃
07-07-14 LS

```

NAME      Klecka_IK-705-I
EXPNO     2
PROCNO    1
Date_     20140707
Time      18.59
INSTRUM    spect
PROBHD     5 mm PABO BB-
PULPROG    zgpg30
TD         65536
SOLVENT    CDCl3
NS         12288
DS         20781.994 Hz
FIDRES     0.454131 Hz
AQ         1.1010548 sec
RG         2050
DM         10.000 usec
DE         0.00 usec
TE         298.0 K
D1         2.0000000 sec
D11        0.0000000 sec
TDO        1
===== CHANNEL f1 =====
NUC1       13C
P1         11.00 usec
P2         22.00 usec
PL1        1.28 dB
PL1W       72.9599040 W
SFO1       125.7225815 MHz
===== CHANNEL f2 =====
CPDPRG2    waltz16
NUC2       1H
P2         80.00 usec
PL2        -1.44 dB
PL2W       13.39 dB
PL1W       27.8861310 W
PL12W      0.62094023 W
SFO2       499.9410064 MHz
SI         131072
SF         125.7100172 MHz
WDW        EM
SSB        0
GB         3.00 Hz
PC         0.50

```




Klecka_IK717-I
¹H NMR in CDCl₃
 02-07-2014 LS

```

NAME      Klecka_IK717-I
EXPNO     1
PROCNO    1
Date_     20140702
Time      15.05
INSTRUM    spect
PROBHD     5 mm PABBO BB-
PULPROG    zg30
TD         64544
SOLVENT    CDCl3
NS         32
DS         0
SWH        5498.534 Hz
FIDRES     0.100002 Hz
AQ         4.9999289 sec
RG         199.71
DW         90.933 usec
DE         6.50 usec
TE         298.0 K
D1         1.00000000 sec
TD0        1

===== CHANNEL f1 =====
SFO1      499.9824999 MHz
NUC1       1H
P1         9.00 usec
PC         131072
SF         499.9800120 MHz
WDW        hc
SSB        0
LB         0.00 Hz
GB         0
PC         1.00
  
```







Klecka_IK717-I
¹³C NMR in CDCl₃
 02-07-2014 LS


```


NAME      Klecka_IK717-I
EXPNO     1
PROCNO    1
Date_     20140702
Time      16.01
INSTRUM    spect
PROBHD     5 mm PABBO BB-
PULPROG    mod
TD         56520
SOLVENT    CDCl3
NS         8192
DS         0
SWH        20791.004 Hz
FIDRES     0.500002 Hz
AQ         0.9066659 sec
RG         199.71
DW         10.820 usec
DE         6.50 usec
TE         298.0 K
CHST2     160.0000000
CHST11    1.0000000
D1         2.00000000 sec
D30        0.00000000 sec
TD0        1

===== CHANNEL f1 =====
SFO1      125.7327116 MHz
NUC1       13C
P1         7.60 usec
PC         15.20 usec
SF         125.7000234 MHz
WDW        EM
SSB        0
LB         2.00 Hz
GB         0
PC         1.40
  
```










```

NAME      KlecKa_IK-668-II
EXPNO     1
PROCNO    1
Date_     20140619
Time      6.14
INSTRUM   spect
PROBHD    5 mm CPBBO 5B
PULPROG   zg30
TD         64210
SOLVENT   DMSO
NS         32
DS         0
SWH        6421.233 Hz
FIDRES     0.100004 Hz
AQ         4.999889 sec
RG         101
DW         77.867 usec
DE         18.00 usec
TE         298.0 K
D1         1.00000000 sec
D10        1
===== CHANNEL f1 =====
SFO1      401.002070 MHz
NUC1       1H
P1         10.00 usec
SI         65856
SF         401.0000037 MHz
WDW        mc
SSB        0
LB         0.00 Hz
GB         0
PC         1.00

```




KLECKA IK-668-II
APT in DMSO-d₆
12-12-13 RA

```

NAME      KLECKA IK-668-II
EXPNO     2
PROCNO    1
Date_     20131212
Time      18.20
INSTRUM   spect
PROBHD    5 mm CPBBO BB-
PULPROG   mod
TD         65536
SOLVENT   DMSO
NS         594
DS         4
SWH        30030.029 Hz
FIDRES     0.458222 Hz
AQ         1.0912410 sec
RG         8192
DW         16.650 usec
DE         8.50 usec
TE         298.0 K
CNST2     160.000000
CNST11    1.0000000
D1         2.00000000 sec
D10        0.0002500 sec
D100       1
===== CHANNEL f1 =====
NUC1       13C
P1         10.00 usec
P2         20.00 usec
PL1        3.55 dB
PL1W       29.94771657 W
SFO1      125.7250687 MHz
===== CHANNEL f2 =====
CPDPRG2   waltz16
NUC2       1H
P2PRG2    80.00 usec
PL2        -2.00 dB
PL12       15.88 dB
PL1W       18.54009846 W
PL12W      0.22093570 W
SFO2      499.9516669 MHz
SI         131072
SF         125.7125969 MHz
WDW        EM
SSB        0
LB         3.00 Hz
GB         0
PC         1.00

```




Klečka_IK679-I
¹H NMR in DMSO
 04-07-2014 LS

```

NAME      Klečka_IK679-I
EXPNO     1
PROCNO    1
Date_     20140704
Time      8.26
INSTRUM   spect
PROBHD    5 mm PABBO BB-
PULPROG   zgpg30
TD         65536
SOLVENT   DMSO
NS         32
DS         0
SWH        5498.534 Hz
FIDRES     0.100002 Hz
AQ         4.95952358 sec
RG         159.11
DW         50.933 usec
DE         6.50 usec
TE         298.0 K
D1         1.00000000 sec
TDO        1

===== CHANNEL f1 =====
SFO1      499.9824999 MHz
NUC1       1H
P1         9.00 usec
PL1        0.00 dB
SF         499.9800040 MHz
WDW        no
SSB        0
LB         0.00 Hz
GB         0
PC         1.00
  
```




Klečka_IK-679-I
¹³C NMR in DMSO

```

NAME      Klečka_IK-679-I
EXPNO     2
PROCNO    2
Date_     20140904
Time      20.40
INSTRUM   spect
PROBHD    5 mm CPTCI 1H-
PULPROG   mod
TD         65536
SOLVENT   DMSO
NS         1024
DS         4
SWH        36057.801 Hz
FIDRES     0.550197 Hz
AQ         0.058158 sec
RG         16400
DW         13.987 usec
DE         6.50 usec
TE         298.0 K
CNST2     145.000000
CNST11    1.0000000
D1         2.00000000 sec
D20        0.0089955 sec
TDO        1

===== CHANNEL f1 =====
NUC1       13C
P1         12.00 usec
PL1        0.00 dB
SF         101.6261200 MHz
SFO1      150.9175888 MHz


===== CHANNEL f2 =====
CPDPRG2   waltz16
NUC2       1H
PCPD2     80.00 usec
PL2        7.00 dB
PL12       25.00 dB
PL2W       0.1920264 W
SF02       600.1324005 MHz
SI         32768
WDW        EM
SSB        0
LB         1.00 Hz
GB         0
PC         1.40
  
```



Klecka_IK-678-I
1H NMR in DMSO

NAME Klecka_IK-678-I
EXPNO 1
PROCNO 1
Date_ 20140215
Time 17.20
INSTRUM spect
PROBHD 5 mm CPTCI 1H-
PULPROG zg30
TD 84174
SOLVENT DMSO
NS 32
DS 2
SWH 8417.509 Hz
FIDRES 0.100001 Hz
AQ 4.9999857 sec
RG 9
DW 59.400 usec
DE 6.50 usec
TE 298.0 K
D1 1.00000000 sec
TD0


===== CHANNEL f1 =====
NUC1 1H
P1 10.00 usec
PL1 8.10 dB
PL1W 5.29101372 W
SFO1 600.1339008 MHz
SI 32768
SF 600.1330064 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00



Klecka_IK-678-I
13C NMR in DMSO

NAME Klecka_IK-678-I
EXPNO 2
PROCNO 1
Date_ 20140215
Time 18.13
INSTRUM spect
PROBHD 5 mm CPTCI 1H-
PULPROG mod
TD 65536
SOLVENT DMSO
NS 1024
DS 4
SWH 36057.801 Hz
FIDRES 0.550197 Hz
AQ 0.0565159 sec
RG 16400
DW 13.897 usec
DE 6.50 usec
TE 298.0 K
CNST2 160.0000000
CNST11 1.0000000
D1 2.00000000 sec
D30 0.00525000 sec
TD0 1


===== CHANNEL f1 =====
NUC1 13C
P1 12.00 usec
P2 24.00 usec
PL1 -1.40 dB
PL1W 107.48942021 W
SFO1 150.9175988 MHz
===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 80.00 usec
PL2 7.00 dB
PL12 25.00 dB
PL2W 6.91614637 W
PL2W 0.10820384 W
SFO2 600.1324005 MHz
SI 32768
SF 150.9063518 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40



Klecka IK-682-II
1H NMR in DMSO

NAME Klecka_IK682-II
EXPNO 1
PROCNO 1
Date_ 20140303
Time 17.50
INSTRUM spect
PROBHD 5 mm CPTCI 1H-
PULPROG zg30
TD 90142
SOLVENT DMSO
NS 32
DS 2
SWH 9014.423 Hz
FIDRES 0.100002 Hz
AQ 4.9995251 sec
RG 10
DW 55.467 usec
DE 6.50 usec
TE 298.0 K
D1 1.00000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 1H
P1 10.00 usec
PL1 8.10 dB
PL1W 5.29101372 W
SFO1 600.134009 MHz
SI 32768
SF 600.1300068 MHz
WDW no
SSB 0
LB 0.00 Hz
GB 0
PC 1.00




Klecka IK-682-II
13C NMR in DMSO

NAME Klecka_IK682-II
EXPNO 2
PROCNO 1
Date_ 20140303
Time 18.43
INSTRUM spect
PROBHD 5 mm CPTCI 1H-
PULPROG zgpg30
TD 65536
SOLVENT DMSO
NS 1024
DS 4
SWH 30007.891 Hz
FIDRES 0.550197 Hz
AQ 0.9089159 sec
RG 10400
DW 13.887 usec
DE 6.50 usec
TE 298.0 K
CNST2 145.000000
CNST11 1.0000000
D1 2.00000000 sec
TD0 0.0098965 sec
TD0 1

===== CHANNEL f1 =====
NUC1 13C
P1 12.00 usec
P2 24.00 usec
PL1 -1.40 dB
PL1W 107.45842621 W
SFO1 150.9175983 MHz


===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 80.00 usec
PL2 7.00 dB
PL12 25.00 dB
PL2W 6.81614837 W
PL12W 0.10802894 W
SFO2 600.1324000 MHz
SI 32768
SF 150.9038228 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40



Klecka_IK-680-I
1H NMR in DMSO

NAME Klecka_IK-680-I
EXPNO 1
PROCNO 1
Date_ 20140215
Time 18.38
INSTRUM spect
PROBHD 5 mm CPTCI 1H-
PULPROG zg30
TD 84174
SOLVENT DMSO
NS 32
DS 2
SWH 8417.509 Hz
FIDRES 0.100001 Hz
AQ 4.9999857 sec
RG 9
DW 59.400 usec
DE 6.50 usec
TE 298.0 K
D1 1.00000000 sec
TD0


===== CHANNEL f1 =====
NUC1 1H
P1 10.00 usec
PL1 8.10 dB
PL1W 5.29101372 W
SFO1 600.1339008 MHz
SI 32768
SF 600.1300061 MHz
WDW no
SSB 0
LB 0.00 Hz
GB 0
PC 1.00



Klecka_IK-680-I
13C NMR in DMSO

NAME Klecka_IK-680-I
EXPNO 2
PROCNO 1
Date_ 20140215
Time 19.31
INSTRUM spect
PROBHD 5 mm CPTCI 1H-
PULPROG gmod
TD 65536
SOLVENT DMSO
NS 1024
DS 4
SWH 36057.861 Hz
FIDRES 0.350197 Hz
AQ 0.0088159 sec
RG 19420
DW 13.897 usec
DE 6.50 usec
TE 298.0 K
CNST2 160.0000000
CNST11 1.0000000
D1 2.00000000 sec
D3 0.00000000 sec
TD0 1


===== CHANNEL f1 =====
NUC1 13C
P1 12.00 usec
P2 24.00 usec
PL1 -1.40 dB
PL1W 107.45843021 W
SFO1 150.9178988 MHz
===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 80.00 usec
PL2 7.00 dB
PL12 25.00 dB
PL2W 6.81614637 W
PL12W 0.10802894 W
SFO2 600.1324005 MHz
SI 32768
SF 150.9028506 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40



Klecka_IK660-I
1H NMR in DMSO
26-03-14 LS

NAME Klecka_IK660-I
EXPNO 1
PROCNO 1
Date_ 20140326
Time 10.07
INSTRUM spect
PROBHD 5 mm BBO BB-1H
PULPROG zg30
TD 56020
SOLVENT DMSO
NS 32
DS 0
SWH 7002.801 Hz
FIDRES 0.125005 Hz
AQ 3.889455 sec
RG 512
DW 71.400 usec
DE 6.00 usec
TE 298.7 K
D1 1.00000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 1H
P1 11.70 usec
PL1 -4.00 dB
PL1W 21.4524498 W
SFO1 499.9533997 MHz
SI 131072
SF 499.9499986 MHz
WDW no
SSB 0
LB 0.00 Hz
GB 0
PC 1.00



Klecka_IK-660-I
13C NMR in DMSO

NAME Klecka_IK-660-I
EXPNO 1
PROCNO 1
Date_ 20140324
Time 18.03
INSTRUM spect
PROBHD 5 mm CPTC 1H-
PULPROG jmod
TD 65530
SOLVENT DMSO
NS 1024
DS 4
SWH 36067.561 Hz
FIDRES 0.550167 Hz
AQ 0.0088159 sec
RG 19400
DW 13.807 usec
DE 6.50 usec
TE 308.0 K
CNST2 145.0000000
CNST11 1.0000000
D1 2.00000000 sec
D20 0.00095655 sec
TD0 1

===== CHANNEL f1 =====
NUC1 13C
P1 12.00 usec
P2 24.00 usec
PL1 -1.40 dB
PL1W 107.48940321 W
SFO1 150.9178988 MHz

===== CHANNEL f2 =====
NUC2 1H
PCPD2 waltz16
PL2 80.00 usec
PL2 7.00 dB
PL12 25.00 dB
PL2W 6.51014453 W
PL12W 0.10802994 W
SFO2 600.1324005 MHz
SI 32768
SF 150.9028528 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40

